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KATP Channel Phosphorylation: Mechanisms and Contribution to 
Vascular Tone Regulation by Vasodilating and Vasoconstricting 
Hormones and Neurotransmitters 
 
by 
Yun Shi 
Under the Direction of Chun Jiang 
 
ABSTRACT 
Contractility of vascular smooth muscles (VSMs) in resistance arteries 
determines systemic blood pressure and blood supplies to local tissues, in which ATP 
sensitive K+ (KATP) channels play a role. The KATP channels that couple metabolic 
state to cellular activity are activated by multiple hormonal vasodilators and inhibited 
by vasoconstrictors.  
To understand the molecular mechanisms for the channel regulation by 
vasodilators, we studied the effects of β-adrenergic receptors on Kir6.1/SUR2B in 
HEK cells. Stimulation of β-adrenergic receptors activated the channels, which relied 
on the GS-protein, adenylyl cyclase, cAMP and PKA system. Using mutational 
analysis, we scanned all the putative PKA sites on Kir6.1 and SUR2B subunits and 
identified two residues (Ser1351 and Ser1387) in SUR2B critical for channel 
activation. In vitro phosphorylation experiments confirmed that Ser1387 but not 
 Ser1351 was phosphorylated in isolated SUR2B peptides. Molecular modeling and 
molecular dynamics simulations reveal that phosphorylation at Ser1387 causes 
interdomain movements in SUR2B subunit. Blockage of the movements by 
engineering a disulfide bond across NBD2 and TMD1 eliminated the PKA-dependent 
channel activation.  
We also studied the molecular basis for the inhibition of vascular KATP 
channels by PKC. In the HEK expression system, we found that the Kir6.1/SUR2B 
channel but not the Kir6.2/SUR2B was drastically inhibited by PKC stimulation. We 
constructed Kir6.1/Kir6.2 chimeras and identified two critical protein domains for the 
Kir6.1 channel inhibition by PKC. The distal C-terminus was the direct target of PKC 
where multiple phosphorylation sites were identified. These phosphorylation sites 
were located in a short sequence with stereotypical sequence repeats. Mutation of any 
decreased the effects of PKC. Joint mutation of all of them prevented the channel 
inhibition by PKC. The proximal N-terminus is also involved in PKC effects without 
phosphorylation sites, suggesting it may play a role in channel gating. 
Thus, this thesis provides experimental evidence for the vascular KATP channel 
modulation by PKA and PKC. Phosphorylation of the Kir6.1 and SUR2B subunits by 
PKC and PKA produce inhibition and activation of the vascular KATP channel, 
respectively, which appears to be one of the molecular bases contributing to vascular 
tone regulation by both vasoconstricting and vasodilating hormones and 
neurotransmitters. 
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6. Specific Aims and Hypotheses 
ATP-sensitive K+ channels (KATP) play an important role in vascular tone 
regulation. The channels couple cellular metabolic activity to the contractility of 
vascular smooth muscles (VSMs). Both vasodilating and vasoconstricting hormones 
and neurotransmitters act on the vascular KATP channels, through which they produce 
changes in membrane potentials, intracellular Ca2+ concentrations and vascular tone.  
Previous studies have shown that the activation of the vascular KATP channels 
by vasodilating hormones relies on the cyclic AMP (cAMP)-dependent protein kinase 
A (PKA) pathway, while the activation of the PKC pathway is necessary for the 
channel inhibition by vasoconstricting hormones. However, the molecular basis for 
the PKA and PKC-dependent modulation of the channels remains illusive. Whether 
these kinases directly phosphorylate the channel proteins is uncertain; there is no 
information about where the phosphorylation sites are located, whether there are other 
signal pathways between these kinases and the channels, and how the channel activity 
is affected by these kinases. 
The studies herein address these issues. The specific aims of this dissertation 
are: 
A. To elucidate the role of PKA in the vascular KATP channel activation 
by vasodilators and identify the molecular substrates of PKA.  
B. To understand the structural basis and gating mechanisms underlying 
PKA-mediated channel activation.  
C. To identify critical protein domains and phosphorylation sites for the 
vascular KATP channels inhibition by PKC.  
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The hypothesis tested for specific aim 1: Activation of the PKA signaling 
pathway underlie the opening of vascular KATP channels by stimulation of β-
adrenergic receptors via direct phosphorylation of the channel proteins.  
The hypothesis for specific aim 2: PKA phosphorylation leads to 
conformational changes in the specific protein domains of SUR2B that eventually 
alter the channel activity.  
The hypothesis addressing specific aim 3: The inhibitory effect of PKC relies 
on pore-forming Kir6.1 subunit instead of the SUR2B subunit that host critical protein 
domains and phosphorylation sites.  
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7. General Introduction: Vascular KATP Channels in Vascular Tone 
Regulation  
7.1. Vascular tone and blood supply  
Systemic blood pressure and blood supplies to local tissues and organs are of 
crucial importance for the human body and are tightly regulated by physiological 
functions, and are controlled by small arteries and arterioles. Their dysregulation 
often leads to catastrophic consequences. The diastolic blood pressure is the 
foundation of blood supply and O2 delivery to all tissues and organs, while regional 
blood flow underlies the functions of individual organs or tissues. Normally, the small 
arteries and arterioles maintain a certain level of contraction, referred to basal 
vascular tension or tone and that maintains systemic blood pressure and various blood 
flows to the local tissues.  
Vascular tone is tightly regulated by a complex of signaling systems involving 
autonomic nerve activity, circulating hormones and local metabolites. Dysregulation 
of vascular tone leads to vascular diseases related to blood pressure such as 
hypertension and abnormality in the functioning of individual organs, such as 
ischemia, hyperemia, shock, etc. The understanding the cellular and molecular basis 
of vascular tone regulation thus will provide information for development of 
therapeutic strategies for vascular diseases.  
7.1.1. Contractility of VSMs and vascular tone 
Smooth muscle cell contractility determines vascular diameters and tone. 
When vascular smooth muscles (VSMs) contract, the vessel constricts, increasing 
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perfusion resistance and reducing blood supplies to the local tissue. When VSMs are 
relaxed, the blood vessel becomes wider, reducing perfusion resistance and increasing 
blood supplies to the tissue. The contractility of VSMs is controlled by autonomic 
nervous system, circulating hormones, local tissue mediators and mechanical forces. 
Regardless of the stimuli, VSM cells contract and develop force utilizing cross-bridge 
cycling of actin and myosin filaments, where Ca2+ serves to initiate contraction. 
7.1.2. Ca2+ and contractile state of VSMs 
Upon receiving contractive signals, cytosolic free Ca2+ in smooth myocytes 
rises from resting level of ~100nM to 500-700nM (Williams & Fay, 1986; Knot et al., 
1998). At the elevated concentrations, Ca2+ binds to calmodulin, a Ca2+-binding 
protein in VSMs. Binding of Ca2+ causes conformational changes in calmodulin and 
exposure of its interaction sites to many target proteins, including myosin light chain 
kinase (MLCK). Activated by a Ca2+-calmodulin complex, MLCK phosphorylates 
myosin light chain (MLC). The MLC phosphorylation augments cycling of myosin 
cross-bridges along actin filaments, and enhances contraction forces of VSMs 
(Seeholzer & Wand, 1989; Stull et al., 1997; Fajmut et al., 2005). Removal of Ca2+ 
from the cytosol leads to the dissociation of calmodulin from MLCK, 
dephosphorylation of MLC by MLC phosphatase and relaxation of the VSMs (Fig. 7-
1).  
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Figure 7-1. Vascular smooth muscle contraction.  
Ca2+ influx from VDCCs is the major source contributing to intracellular Ca2+ 
elevation. Ca2+ causes muscle contraction through a series of biochemical reactions.  
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The cytosolic Ca2+ comes from two sources, extracellular spaces and 
intracellular Ca2+ stores (mostly from sarcoplasmic reticulum, or SR). Ca2+ 
concentrations in both the extracellular space and SR are in the millimolar to 
hundreds of millimolar range, much higher than that in the cytosol (~100nM at rest). 
Depolarization of the cell activates voltage-dependent Ca2+ channels (VDCCs) on the 
sarcolemma triggering Ca2+ influx (Nelson et al., 1990b; Thorneloe & Nelson, 2005). 
Changes in blood pressure and shear force also affect Ca2+ entry via transient 
potential channels (TRP)(Beech et al., 2004; Remillard & Yuan, 2006). Ca2+-release 
from the SR via IP3 receptors (Missiaen et al., 1999) and/or ryanodine receptors 
(Hisayama et al., 1990; Neylon et al., 1995) is another source of cytosolic Ca2+. 
Unlike cardiac and skeletal muscles where Ca2+ mainly comes from the SR, Ca2+ 
influx through the VDCCs is the major source of cytosolic Ca2+ in VSMs (Thorneloe 
& Nelson, 2005). Therefore, agents and cellular activity affecting VDCC activity have 
a major impact on cytosolic Ca2+ levels and thus vascular tone. 
As the name indicates, the VDCCs open or close depending on the voltage 
across the plasma membrane. VDCCs in VSMs consist of L-type and T-type Ca2+ 
channels (Ganitkevich & Isenberg, 1990; Smirnov & Aaronson, 1992; Snutch et al., 
2001), both of whose activities increase upon depolarization and decrease upon 
hyperpolarization. The membrane potentials reported in variety of blood vessels are 
typically between -40 and -60mV (Nelson & Quayle, 1995). In this range, the 
relationship between activity of Ca2+ channels and membrane potentials is rather 
linear and steep, allowing a small change in membrane potential to cause a large 
alteration in Ca2+ influx (Nelson et al., 1990b). 
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 7.1.3. The membrane potential in VSMs and K+ channels 
The membrane potentials in VSMs rely on K+, Cl- and leak Na+ currents 
(Nelson & Quayle, 1995). The K+ conductance (GK) is regulated by environmental 
factors and contributes to moment-to-moment changes in vascular tone. Several types 
of K+ channels exist in VSMs, including voltage-gated K+ channels (Kv), Ca2+-
activated K+ channels (KCa), inward rectifier K+ channels (Kir) and ATP-sensitive K+ 
channels (KATP) (Nelson & Quayle, 1995; Jackson, 2005).  
Activity of these channels is differentially regulated by changes in 
extracellular signals, intracellular second messengers and other chemical and physical 
stimuli. The Kv channels are open upon depolarization; bring the membrane 
potentials back to the rest level or repolarization. Because of the existence of Kv 
channels, the membrane potentials of VSMs generally cannot go above 0mV under 
physiological conditions. The Ca2+-activated K+ channels act as a feedback system 
that repolarizes the VSM cells, decreases cytosolic Ca2+, and prevents sustained 
contraction. The inward rectifier K+ channels alter the vascular tone according to 
changes in K+ levels in the blood. The KATP channels are thought to be particularly 
important as their activity is subject to regulation by various pharmacological and 
endogenous vasoregulators, as well as metabolic activity that can directly affect blood 
flow (Quayle et al., 1997; Cole & Clement-Chomienne, 2003; Seino & Miki, 2003).  
7.1.4. KATP channels are involved in regulation of VSM membrane potential  
The role of vascular KATP channels in controlling VSM membrane potential 
has been established by early pharmacological studies. A number of synthetic 
compounds, known as K+ channel openers (KCOs, including diazoxide, nicorandil, 
cromakalim and pinacidil), increase K+ conductance in VSMs and decrease systemic 
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blood pressure (Rhodes & Sutter, 1971; Andersson, 1973; Standen et al., 1989; 
Winquist et al., 1989; Longmore et al., 1991). Despite the structural diversity, KCOs 
work exclusively on KATP channels, resulting in hyperpolarization in VSM membrane 
potential and vasodilation (Standen et al., 1989; Edwards & Weston, 1993). For 
example, 10μM cromakalim activates KATP channels in rabbit cerebral artery and 
human pulmonary artery, and hyperpolarizes the VSM cell by ~20mV (Nelson & 
Quayle, 1995; Cui et al., 2002). Such large hyperpolarization closes the voltage-gated 
Ca2+ channels and leads to complete relaxation of vessels. In contrast, glibenclamide, 
which inhibits KATP channels, causes a significant depolarization in some vessel beds 
such as coronary and mesenteric arteries (Nelson et al., 1990b; Garland & 
McPherson, 1992), suggesting the involvement of KATP activity in basal vascular tone. 
Although in renal, cerebral and pulmonary arteries, glibenclamide does not affect 
basal tone probably because the basal activity of KATP channels is low in these artery 
beds, the KATP channels regulate tone during metabolic press (Wiener et al., 1991; 
Reid et al., 1993; Loutzenhiser & Parker, 1994).  
7.2. Molecular aspects of KATP Channels  
7.2.1. Discovery of KATP channels  
Using inside-out patches, Noma (Noma, 1983) reported that K+ channels in 
the cardiac muscle were strongly inhibited by intracellular ATP. Such ATP-sensitive 
K+ channels have also been observed in other tissues such as pancreas (Ashcroft et al., 
1984; Cook & Hales, 1984), skeletal muscles (Spruce et al., 1985), smooth muscles 
(Standen et al., 1989) and neurons (Ashford et al., 1988; Amoroso et al., 1990; 
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Bernardi et al., 1993). Studies on the native KATP channels have revealed variability in 
their biophysical and pharmacological properties.  
In general, KATP channels are inhibited by ATP and activated by Mg2+-
nucleotide diphosphates (NDP) in the cytosol (Zhang & Bolton, 1995; Aguilar-Bryan 
et al., 1998; Ashcroft & Gribble, 1998; Masia et al., 2005; Nichols, 2006). These 
channels are also activated by some, if not all, KCOs such as diazoxide, pinacidil and 
cromakalim (Edwards & Weston, 1993; Ashcroft & Gribble, 2000; Matsuoka et al., 
2000; Yamada & Kurachi, 2004; Moreau et al., 2005). In addition, they are inhibited 
by sulfonylureas including glibenclamide (or glybenclamide, glyburide), glimepiride, 
glipizide, gliquidone, gliclazide, tolazamide and tolbutamide (Standen et al., 1989; 
Zhang & Bolton, 1995; Ashcroft & Gribble, 2000; Reimann et al., 2001). KATP 
channels are defined by a combination of biophysical and pharmacological properties. 
KATP channels in different tissues, however, display different single channel 
conductance as well as different sensitivities to physiological and pharmacological 
agents (nucleotides, KCOs and sulfonylureas) (Ashcroft, 1988; Quayle et al., 1997), 
suggesting diversity of KATP channels. Indeed multiple genes encoding the channel 
proteins and splicing variants have been found.  
7.2.2. KATP channels are composed of Kir6.x and SURx 
KATP channels are composed of two different subunits, Kir6.x and SURx, with 
the 4:4 stoichiometry (Clement et al., 1997; Inagaki et al., 1997; Shyng & Nichols, 
1997). Each type of subunit is encoded by a different gene family: pore-forming 
subunits (Kir6.x, α-subunits) and auxiliary sulfonylurea receptors (SURx, β-subunits). 
Using a partial sequence of Kir3.1 cDNA as probe, Inagaki et al. (Inagaki et al., 
1995b) cloned the Kcnj8 (Kir6.1) gene from a rat pancreatic islet cDNA library. The 
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Kir6.1 gene is expressed ubiquitously in all tissues, encoding a protein of 424 amino 
acids. Using Kir6.1 cDNA as a probe, the Kcnj11 (Kir6.2) gene was cloned from a 
human genomic library and a rat cDNA library (Inagaki et al., 1995a) as well as a 
mouse cDNA library (Sakura et al., 1995). Abundant expression of Kir6.2 was found 
in the pancreas as well as heart, brain and skeletal muscles. The Kir6.2 protein has 
390 amino acids in length, sharing ~70% identity with Kir6.1. Kir6.1 and Kir6.2 
belong to the inward rectifier K+-channel subfamily based on their homology; they are 
43-46% identical to other members in Kir subfamily (Inagaki et al., 1995a). 
Two genes encoding sulfonylurea receptors have been cloned so far, namely 
abcc8 and abcc9 (SUR1 and SUR2) (Aguilar-Bryan et al., 1995; Inagaki et al., 1996). 
There are splicing variants of SUR2 mRNAs, the major ones encoding SUR2A and 
SUR2B (Isomoto et al., 1996). The SUR2B differs from SUR2A in the last 42 and 45 
residues in rodents and humans respectively. The SUR2B C-terminus is more 
homologous to SUR1 than is SUR2A. Splicing variances in SUR1 have also been 
reported (Sakura et al., 1999; Gloyn et al., 2001; Hambrock et al., 2002). In vivo, the 
Kir6.x and the SURx are expressed in plasma membranes to form functional channels 
guided by ER retention signaling sequences in both subunits (Zerangue et al., 1999).  
Since Kir6 and SUR subunits were cloned, expression systems have been used 
to clarify biophysical and pharmacological properties of the channels and compare to 
their native counterparts. All combinations of Kir6.x (Kir6.1 and Kir6.2) and SURx 
(SUR1, SUR2A and SUR2B) can form functional channels (Aguilar-Bryan et al., 
1998; Ashcroft & Gribble, 1998). It is now known that all Kir6.2-containing channels 
have a unitary conductance of 70-80pS while Kir6.1-containing channels are 30-35pS 
(Inagaki et al., 1995a; Inagaki et al., 1995b; Isomoto et al., 1996; Yamada et al., 
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1997; Wang et al., 2003). Kir6.1/Kir6.2 can also form heteromeric channels in 
expression system with single channel conductance between typical Kir6.2 and Kir6.1 
channels (Cole et al., 2000; Cui et al., 2001), although whether there are such 
channels in real tissues is still unknown. In inside-out patches, Kir6.2 channels are 
spontaneously open while Kir6.1 channels are completely closed in the absence of 
nucleotides (Kondo et al., 1998). Original reports suggested that Kir6.1 and Kir6.2 
channels were clearly different in their sensitivity to ATP inhibition (Yamada et al., 
1997); however, this has not been completely accepted in the field (Babenko et al., 
2000b; Babenko & Bryan, 2001). SURx are known to determine the channel 
sensitivity to activation by Mg2+-nucleotides and KCOs, and to determine inhibition 
by sulfonylureas (Ashcroft & Gribble, 1998; Bryan & Aguilar-Bryan, 1999; Seino, 
1999). Therefore channels consisting of different SURx have different 
pharmacological properties. In contrast to Kir6.x, SURx cannot form heterotetramers 
in expression systems (Giblin et al., 2002). Combinations of Kir6.x and SURx form 
KATP channels accounting for the variety of channel properties found in various 
tissues. With pharmacological evidence as well as mRNA expression data in tissues, it 
is now accepted that the Kir6.2/SUR1 channel is the pancreatic isoform (Ashcroft & 
Gribble, 2000), the Kir6.2/SUR2A combination represents the KATP channels in 
cardiac and skeletal muscles (Isomoto et al., 1997), and the KATP channels in vascular 
smooth muscles are likely to be made of Kir6.1/SUR2B (see Chapter 7.3).  
7.2.3. Functions of Kir6 subunits  
The Kir6 pore-forming subunits belong to the inward rectifier K+ subfamily. 
Like other members in the subfamily, Kir6.1 and Kir6.2 possess two transmembrane 
segments (TM1 and TM2) with both N- and C-termini located intracellularly. A pore-
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loop is located between TM1 and TM2. Four Kir6 proteins form a tetramer in which 
four ‘GFG’ filtering segments form a selective pore for K+ to pass (Clement et al., 
1997; Inagaki et al., 1997; Shyng & Nichols, 1997; Doyle et al., 1998). TM2s line the 
permeation pathway and converge to form a gate by phenylalanine residues at the 
cytoplasmic face of the pore (Rojas et al., 2007). TM1s stand surrounding TM2s and 
transfer N-terminus gating signals to the pore by interacting with TM2 (Cui et al., 
2003; Wang et al., 2005; Wang et al., 2007).  
Tucker et al (Tucker et al.) have found that by deleting the distal C-terminus 
(26-36 residues, where the ER retention signal is located), Kir6.2 can form functional 
K+ channels in the absence of SURx. The engineered Kir6.2s are inhibited by ATP 
but not activated by NDP, indicating that ATP inhibition is an intrinsic property of 
Kir6 subunits. Direct evidence for ATP-binding has been shown using photoaffinity 
labeling of Kir6.2 by [γ-32P]-8-azido-ATP (Tanabe et al., 2000). Further studies 
demonstrated the ATP binding sites are likely located on both N-terminus and C-
terminus including Arg50, Lys185, Ile183, Arg201 and Gly334 (Tucker et al., 1997; 
Drain et al., 1998; Tucker et al., 1998; Shyng et al., 2000a). Via homology modeling 
based on the bacterial Kir channel (Kuo et al., 2003) and the cytoplasmic portion of 
the Girk1 (Kir3.1) channel (Nishida & MacKinnon, 2002), ATP binding pockets in 
Kir6.2 have been described (Antcliff et al., 2005). These binding pockets involve 
binding sites from adjacent Kir6.2 subunits.  
Using the truncated forms of Kir6.2, studies in our lab have demonstrated that 
the KATP channels are sensitive to pH changes in the physiological range, with His175 
being the titration site (Xu et al., 2001a; Wu et al., 2002a; Wu et al., 2002b). The pH 
sensitivity of KATP channels is involved in modulation of contractility of cardiac 
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muscles under heavy exercise (Li et al., 2005) and regulation of vascular tone by 
acidosis (Wang et al., 2003). Other modulators such as phospholipids and long chain 
acyl CoA (LC-CoA) have been shown to antagonize the ATP inhibitory effects on 
KATP channels (Hilgemann & Ball, 1996; Fan & Makielski, 1997; Baukrowitz et al., 
1998; Shyng & Nichols, 1998). The molecular and structural basis for channel 
regulation by PIP2 has been studied using mutational analysis and homology 
modeling. Multiple positive charged residues in N- and C-termini on Kir6.2 bind PIP2 
(Shyng et al., 2000b; Schulze et al., 2003a), are shown to form binding pockets in a 
homology modeling study (Haider et al., 2007). LC-CoAs share some of those 
positive charged residues and might use same binding pockets (Schulze et al., 2003b; 
Manning Fox et al., 2004).  
7.2.4. Functions of SUR subunits 
The SUR subunits are large proteins with multiple domains. They belong to 
the ABC transporter superfamily rendering a typical ABC ‘core’, two clusters of 
transmembrane domains (TMD1 and TMD2) each containing 6 transmembrane helices 
(TMHs) and two nucleotide-binding domains (NBD1 and NBD2). NBD1 is linked to 
the C-terminal of TMD1, and NBD2 to TMD2. Besides the ‘core’, there is an 
additional TMD0 containing 5 helices linked to TMD1 with intracellular linker-0 
(ICL0). Therefore, the whole protein spans the membrane 17 times with the N-
terminus located extracellularly. Both NBDs are located inside, containing the 
canonical phosphate-binding Walker A and Walker B motifs and other conserved 
motifs such as signature sequence, Q-loop and H-loop, hallmarks in all ABC proteins. 
SURx tightly bind 8-azido ATP in NBD1, suggesting NBD1 is a high-affinity ATP 
binding motif (Matsuo et al., 2000). Mg2+ potentiates nucleotide binding in NBD2, 
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where hydrolysis seems to occur (Matsuo et al., 1999; Matsuo et al., 2000). The 
hydrolysis of ATP by NBD2 is proposed to provide energy to rearrange TMD1 and 
TMD2 (Yamada & Kurachi, 2004). However, this process is still not understood. 
First, ADP can cause channel activation in the absence of ATP, suggesting the energy 
from hydrolysis might not be necessary. Second, ATP hydrolysis and TMD 
rearrangements are associated with substrate transport in other ABC transporters, 
whereas in SURx such a process is not required. Third, how NBDs interact with 
TMDs and how nucleotide-binding causes TMDs rearrangements is not clear.  
The SURx subunits are targets for binding of multiple inhibitory and 
stimulatory compounds. Sulfonylureas such as glibenclamide and tolbutamide, inhibit 
all KATP channels. K+ channel openers, such as diazoxide, pinacidil and 
lecovromakalin, activate KATP channels with variable potency depending on the SUR 
subunits. The molecular basis for sulfonylureas and KCOs’ effects are far from being 
well understood although some critical sites have been revealed in the TMDs 
(Babenko et al., 2000a; Moreau et al., 2005).  
7.2.5. Coupling between SUR and Kir subunits in channel gating 
How do SURx and Kir6.x interact? This issue is obviously important for 
understanding SUR-mediated channel gating. Using chimeras between TAP1, a 
human multiple drug-resistance protein, and SUR1, Schwanpasch et al. (2000) 
demonstrate that TMDs in SURx are critical for interaction with Kir6.x. Rainbow et al 
(2004) propose that segments of the NBD2 directly interact with Kir6.2. The TM1 in 
Kir6.2 and N-terminal flanking sequences are believed to be involved in the Kir-SUR 
interaction (Schwappach et al., 2000). The proximal C-terminus of Kir6.2 is also 
proposed to be another site of interaction (Giblin et al., 1999). Two groups have 
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reported that SUR1-TMD0 forms complexes with Kir6.2 (Babenko & Bryan, 2003; 
Chan et al., 2003). The TMD0 also enhances the Kir6.2 (C-terminus truncated form) 
channel activity in the absence of the core of SUR1. This ‘mini-KATP’ channel clearly 
lacks many properties of full channels and is insensitive to sulfonylureas, Mg2+-NDP 
and KCOs, but retains ATP inhibition (Babenko & Bryan, 2003), implying the 
important roles of SUR-core in sulfonylurea-mediated inhibition and NDP-mediated 
activation. However, even with these data in hand, how SURx transfers gating signal 
to Kir6.x is far from clear. One of the reasons is the lack of the understanding of SUR 
structures, such as how TMD assembly and how NBD interact. Structural information 
about SURx will certainly help the understanding of SUR-mediated channel gating.  
7.3. Molecular components of Vascular KATP Channels 
7.3.1. Kir6.1/SUR2B isoform resembles a native KATP channel in VSMs  
The single channel conductance of native vascular KATP channels is reported 
to be from 10 to 280pS, a range so wide that it can only be explained by multiforms of 
channels (Quayle et al., 1997). The channels with small-middle conductance (20-
50pS) recorded under symmetric ~140mM K+ (Quayle et al., 1997) are not 
spontaneously open in inside-out patches. To record currents from the channels 
requires the presence of MgNDP or KCOs at cytosolic side of the patches. The 
channel sensitivity to ATP inhibition is also variable. Some reports suggest the 
channels are inhibited by 10μM to several hundred μM ATP (See review by (Quayle 
et al., 1997)), while some report ATP-insensitivity (Beech et al., 1993; Zhang & 
Bolton, 1995; Zhang & Bolton, 1996). This group of channels has mostly been 
studied as recombinant Kir6.1/SUR2B channels in expression systems (Yamada et al., 
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1997). Some channels with a slightly larger conductance of 70-80pS in high K+ 
(Zhang & Bolton, 1996) and ~50pS at 60/140mM K+ (Cole et al., 2000) can be 
explained as the Kir6.2/SUR2B isoform (Isomoto et al., 1996). The ‘KATP’ channels 
with large conductance over 100pS are also sensitive to ATP, Glibenclamide and 
KCOs (Standen et al., 1989). Such large conductance ‘ATP-sensitive’ K+ channels are 
also reported in neurons (Jiang et al., ; Jiang & Haddad, 1997). Their molecular basis, 
however, is still unknown. 
When Kir6.1 and SUR2B were cloned, both cDNAs were reported to be 
ubiquitously expressed, consistent with the distribution of blood vessels. The 
Kir6.1/SUR2B channel has a unitary conductance of ~30pS with no obvious voltage-
dependent rectification (Yamada et al., 1997). The Kir6.1/SUR2B channel is 
completely closed in the absence of nucleotides and reactivated by NDPs. The 
channel is activated by KCOs and inhibited by glibenclamide. ATP appears to be 
required to maintain the channel activity and only causes inhibition at high 
concentration (>5mM). Therefore, the Kir6.1/SUR2B channel has most properties of 
the KNDP channels found in vascular smooth muscles (Beech et al., 1993; Zhang & 
Bolton, 1996; Cole et al., 2000).  
7.3.2. Vascular expression 
The molecular properties of native KATP channels in VSMs have been 
investigated in mRNA/protein expression analysis in addition to electrophysiological 
observations. Table 7-1 summarizes the published molecular properties of native KATP 
channels in VSMs. In cultured human pulmonary artery smooth muscles, 
levcromackalim activated glibenclamide sensitive K+-currents with a unitary 
conductance of ~29pS, comparable to the Kir6.1/SUR2B expressed in HEK293 (Cui 
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et al., 2002). The expression of all possible KATP subunits was checked using RT-PCR 
in the same study; Kir6.1 and SUR2B mRNAs but not Kir6.2, SUR1 and SUR2A 
were found in cultured smooth muscles from the tissue (Table 7-1). In rat aorta, the 
Kir6.1 and SUR2B mRNAs were found to be downregulated by growth hormones 
using microarrays (Tivesten et al., 2004). In addition to Kir6.1 and SUR2, the mRNA 
of Kir6.2 is reported (Ren et al., 2003; Gao et al., 2005) in rat aorta. Kir6.2 was also 
found in human corpus cavernosum but appeared to be much less than Kir6.1 
suggesting a ratio of 3:1 or 4:0 (Insuk et al., 2003). In our lab, we found the Kir6.1 
and SUR2B mRNA were more abundantly expressed in resistance arteries than large 
arteries, supporting the function of the channels in regulation of vascular tone (Li et 
al., 2003). The channel expression at protein level has been reported. In the coronary 
resistance arteries, both SUR2 and Kir6.1 are expressed, while Kir6.2 and SUR1 are 
absent (Morrissey et al., 2005). In rat basilar and middle cerebral arteries, the 
expression of Kir6.1 and SUR2B is predominant while moderate expression of Kir6.2 
and SUR1 are detected using real-time PCR and western blot (Ploug et al., 2006). In 
cultured smooth muscle cells from rat basilar artery, however, another research group 
did not observe Kir6.2 mRNA using RT-PCR (Santa et al., 2003). It is not known 
whether the cultured cells have altered expression pattern or the real tissues contain 
contamination from endothelial KATP channels. Therefore, the reports of channel 
expression patterns in VSMs are not consistent even from the same tissues. Difference 
in tissue preparation or the sensitivity of detecting methods might contribute to the 
discrepancy. Nevertheless, these studies suggest that the Kir6.1/SUR2B is the major, 
if not the only, component in VSMs.  
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Table 7-1. Expression of KATP channels in vascular smooth muscles. 
Tissues Kir6.1 Kir6.2 SUR1 SUR2A SUR2B SUR2 methods References 
coronary resistance vessels + - -   + IH  Morrissey,2005 
human placental vasculature + Na NA NA NA  RT-PCR/Western blot Wareing, 2006 
rat tail artery and aorta + + NA   + RT-PCR Gao, 2005 
rat aorta  + NA NA NA +  microarray Tivesten, 2004 
rat aorta  + + NA NA + RT-PCR Ren, 2003
human corpus carvernosum  + + - - +  RT-PCR Insuk, 2003 
cultured SM from pulmonary arteries + - - - +  RT-PCR Cui, 2002 
kidney vascular smooth muscles + NA NA NA NA  Western, IH, in situ, EM Zhou, 2007 
rat basilar and middle cerebral arteries + + + - +  Western, Real-Time PCR Ploug, 2006 
cultured SM from rat basilar artery + - NA NA +  RT-PCR Santa,2003 
  
List of published data for expression of KATP channels in vascular smooth muscles. SM, smooth muscle cells. +, positively detected. -
, negatively detected. NA, not tested. IH, immunohistochemistry. EM, electron microscopy. RT-PCR, reverse transcriptive PCR. in situ, in 
situ hybridization.  
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In some vessels such as aorta, Kir6.2 expression is significant, which could form 
Kir6.2/SUR2B channel or potentially heteromeric channels in the combination of 
Kir6.1/Kir6.2/SUR2B. The presence of SUR2A and SUR1 is not widely accepted in 
VSMs (Cole & Clement-Chomienne, 2003; Seino & Miki, 2003). 
7.3.3. Evidence from gene knockout animals  
Recently all four genes encoding KATP channels have been successfully knocked 
out in mice (Miki et al., 1998; Seghers et al., 2000; Chutkow et al., 2001; Miki et al., 
2002; Shiota et al., 2002). While Kir6.2 or SUR1 knockout mostly damages the glucose 
homeostasis (Miki et al., 1998; Seghers et al., 2000; Shiota et al., 2002), knockout of 
Kir6.1 or SUR2 impairs coronary artery function (Chutkow et al., 2001; Miki et al., 
2002). These animals show high death rates resulting from myocardial ischemia. 
Electrophysiological recording demonstrates that the animals develop spontaneous 
elongation of ST segments. In Kir6.1 knockout mice, pinacidil can induce KATP currents 
in cardiac muscles but not in coronary artery smooth muscles, suggesting Kir6.1 is the 
critical component of KATP channels in coronary artery. Without the protection by KATP 
channels in coronary arteries, the animals develop Prinzmetal angina and die suddenly 
(Chutkow et al., 2001; Miki et al., 2002). Studies in KATP KO mice thus further 
demonstrate Kir6.1 and SUR2 encode vascular KATP channels.  
 
 
20
7.4. Regulation of the Channel Activity  
7.4.1. Metabolites  
Like KATP channels in other tissues, vascular KATP channels can couple 
intracellular metabolic state to membrane potentials. Inhibition of cellular metabolism 
with metabolic poisons, substrate depletion, or hypoxia has been reported to cause the 
channel activation in several tissues (for review, see (Quayle et al., 1997)). ATP, ADP 
and pH are three major factors that change during metabolic stress and contribute to KATP 
channel modulation. ATP inhibits vascular KATP channels, although the sensitivity varies 
among reports (Quayle et al., 1997). ATP concentrations, however, are well maintained 
in smooth muscles under physiological condition. ATP depletion only happens under 
extreme pathophysiological conditions (Quayle et al., 1997). Therefore, the release of 
ATP inhibition might contribute to channel activity only under severe conditions. In 
contrast, the ADP concentrations change in a relatively wider range, thus it is one of the 
critical factors mediating metabolic regulation on vascular KATP channels. With stress 
challenges such as hypoxia and hypercapnia, extracellular and intracellular pH also drops 
significantly, which also drastically activate vascular KATP in basilar artery and 
mesenteric artery (Santa et al., 2003; Wang et al., 2003).  
7.4.2. Hormonal vasodilators  
Multiple vasodilating neurotransmitters and hormones have been shown to 
activate KATP channels in several vessel beds (Fig. 7-2). Calcitonin gene-related peptide 
(CGRP) is a potent endogenous vasodilator found in perivascular nerves in many tissues. 
CGRP activates KATP channels in smooth muscle cells isolated from porcine coronary 
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arteries (Miyoshi & Nakaya, 1995) and rabbit mesenteric arteries (Nelson et al., 1990a; 
Quayle et al., 1994). CGRP hyperpolarizes the smooth muscle cells in intact mesenteric 
arteries and causes vasodilation that is partially abolished by glibenclamide. The cAMP-
PKA pathway is involved in the CGRP effect.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-2. List of vasoactive agents that affect KATP channel activity 
CO2 activates KATP channel via decrease in intracellular pH. Other vasodilators activate 
KATP channels in a PKA dependent manner. Most vasoconstrictors inhibit KATP channels in a PKC 
dependent manner. 
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Vasoactive intestinal polypeptide (VIP) is another potent vasodilator found in 
perivascular nerve terminals in coronary and cerebral artery beds. VIP activates KATP 
channels in smooth muscles isolated from rat mesenteric artery and Kir6.1/SUR2B 
channel expressed in HEK293 cells via protein kinase A (Yang et al., 2007).  
Adenosine is an important endogenous vasodilator in the coronary circulation, in 
which adenosine induces vasodilation that is inhibited by glibenclamide (Belloni & 
Hintze, 1991; Nakhostine & Lamontagne, 1993; Orito et al., 1993; Toombs et al., 1993; 
Akatsuka et al., 1994; Randall, 1995). The effects of adenosine seem to be mediated by 
adenosine A2 receptors known to activate the PKA signaling pathway (Akatsuka et al., 
1994; Kleppisch & Nelson, 1995).  
Endothelium-release nitric oxide (NO) relaxes VSMs by several mechanisms, one 
of which is mediated via activation of KATP channels (Murphy & Brayden, 1995; 
Ishibashi et al., 1998). The intracellular signal pathway presumably involves cGMP-
PKG, while cGMP might also activate PKA as a potential mechanism of the channel 
activation (Quayle et al., 1997). Another KATP channel activator is endothelium-derived 
hyperpolarizing factor (EDHF) (Brayden, 1990). EDHF is a mixture of several 
epoxyeicosatrienoic acids (EETs) that activate KATP channels in mesenteric artery 
through the cAMP-PKA pathway (Ye et al., 2005; Ye et al., 2006).  
7.4.3. Vasoconstrictors  
Vasoconstrictors contract VSMs through multiple mechanisms. One of them is 
via inhibition of KATP channels. Endothelin (Miyoshi et al., 1992; Kasemsri & Armstead, 
1997; Thorin et al., 1998), vasopressin (Wakatsuki et al., 1992) and angiotensin II 
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(Miyoshi & Nakaya, 1991; Kubo et al., 1997; Kawabata et al., 2001; Sampson et al., 
2007) activate Gq, phospholipase C and protein kinase C. Blockade of PKC activity using 
pharmacological tools eliminates the inhibitory effects on KATP channels. Furthermore, 
angiotensin II may inhibit KATP channels by inhibiting PKA activity (Hayabuchi et al., 
2001b). Since the KATP channels are involved in rest membrane potential, the PKC 
inhibition is significant in basal tone regulation. Besides, and probably more importantly, 
the PKC inhibition facilitates vasoconstriction by blockade of KATP activation.  
7.5. Questions and potential solutions  
7.5.1. The questions about vascular regulators 
Experimental evidence suggests that the effects of PKA and PKC on KATP 
channel activity are critical for vascular tone regulation. However, the underlying 
mechanisms remain elusive, though the phenomena have been discovered for more than 
ten years. The molecular substrates of PKA and PKC are unclear. Do PKA and/or PKC 
directly phosphorylate the channel proteins? If so, which subunit is the target? Where are 
the phosphorylation sites? If both kinases directly target the channel proteins, why can 
one produce channel activation and the other cause channel inhibition? What is the 
underlying gating mechanism upon phosphorylation? If the kinase(s) does not 
phosphorylate the channel proteins directly, what are the signaling molecules targeted 
directly by the kinase(s)? It is clear that addressing these questions has a major impact on 
the understanding of circulation regulation regarding the importance of the channels in 
vascular tone regulation.  
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7.5.2. Potential solutions  
To address the channel regulations by PKA and PKC, several experimental 
techniques have been considered in the original experimental design conducted in this 
thesis.  
7.5.2.1. Heterologous expression systems and real tissues  
The heterologous expression systems and mutational analysis have been used to 
identify the critical sites for ATP and PIP2 binding on Kir6.2 discussed in above. The 
same strategy has been used to identify phosphorylation sites in Kir6.2/SUR1 (Beguin et 
al., 1999; Lin et al., 2000). Comparing to real tissues, the heterologous expression 
systems allow us to manipulate channel proteins. However, when the data from the 
expression systems are translated to the real tissues, we need pay attention: the real 
tissues may not possess the same signaling pathway as that in expression system. For 
instance, the Kir6.2/SUR1 channel is activated by PKA in expression systems (Beguin et 
al., 1999; Lin et al., 2000), while activation of Gs system in pancreatic β-cells seems to 
inhibit the channel (Kang et al., 2006). A minimal requirement for using heterologous 
expression systems is that the factor investigated should has comparable effects on 
channels in expression systems and in real tissues. The Kir6.1/SUR2B channels are 
activated by protein kinase A in HEK293 cells with comparable sensitivity to those in 
real tissue (Quinn et al., 2004). The Kir6.1/SUR2B channels also present the same PKC 
inhibitory effects as native channels (Thorneloe et al., 2002). Therefore, using a 
combination of heterologous expression systems and mutational analysis might provide 
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valuable information for understanding the underlying mechanisms of PKA activation 
and PKC inhibition.  
7.5.3.2. Chimeras vs. mutational analysis 
Mutational analysis is a traditional method in identification of phosphorylation 
sites. PKC and PKA phosphorylate serine and theronine residues within a consensus 
sequence, thus allowing us to predict the putative sites. With the putative phosphorylation 
sites in hand, mutagenesis can be applied to target them one by one to analyze their 
function in phosphorylation. Mutational analysis has been used in our lab in identification 
of PKC sites in Girk channels (Mao et al., 2004) and identification of the PKA sites in 
Kir6.1/SUR2B channel in this thesis. However, this method has drawbacks. If the protein 
has multiple functional phosphorylation sites, the effects may not be strictly additive. In 
this case, other strategies can be considered such as chimeras. To identify critical protein 
domains using a chimeric approach, two proteins must be similar in their protein 
sequences, and have clearly different responses (better if completely opposite). The 
Kir6.1 and Kir6.2 are highly similar to each other with ~70% identity in the primary 
sequences. However, all Kir6.2-containing channels are activated or do not respond to 
PKC, while Kir6.1-containing channels are inhibited by PKC (detailed in chapter 12). 
The effects are clearly opposite. So in this thesis we adopted a chimeric strategy to 
complement the mutational analysis and found critical motives for PKC inhibition.  
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7.5.3.3. Molecular modeling in understanding phosphorylation-associated channel 
gating  
The molecular modeling strategy can further explain the molecular basis of the 
channel gating from structural views, providing a more detailed understanding of the 
basic mechanism. This has been applied to understanding the ATP and PIP2 binding 
pockets in Kir6.2 (Antcliff et al., 2005; Haider et al., 2007). To use this strategy it is 
necessary to find the appropriate structural template that generally comes from the same 
protein family. Kir6.1 belongs to the inward rectifier K+ channel subfamily. The cytosolic 
portions of mammalian Kir3.1 (Nishida & MacKinnon, 2002) and Kir2.1 (Pegan et al., 
2005) have been crystallized with high resolution. The transmembrane and core regions 
have been resolved for the entire bacterial KirBac1.1 (Kuo et al., 2003). Therefore Kir6.1 
and Kir6.2 subunits can be modeled using these known crystal structures. SUR subunits 
belong to ATP-binding cassette transporter (ABC) superfamily. The ABC transporters 
are large proteins with multiple domains including an ABC-core that is composed of two 
nucleotide-binding domains (TMDs) and two clusters of transmembrane domains 
(TMDs). In SURx, the additional TMD0 is linked to the N-terminus of the ABC-core. 
Recently several ABC proteins have been crystallized. Among them is SAV1866, a 
homologue of SURx. In this thesis, we have found a critical PKA site is located on the 
SUR2B subunit. Thereby the SAV1866-based SUR2B model may provide structural 
information for the PKA-mediated gating. On the other hand, we have found that the 
PKC sites are all located in distal C-terminus of Kir6.1. Unfortunately, the resolved 
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crystal structures of Kir2.1 and Kir3.1 lack this region, and cannot be used to understand 
PKC-mediated gating mechanisms. 
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8. Significance 
Small arteries and arterioles regulate diastolic blood pressure and regional blood 
flow. Diastolic blood pressure controls systemic functions, while the regional blood flow 
determines activity of each individual organ and tissue. Therefore, the vascular tone or 
tension, to a large degree, determines the functional status of the system and local tissues. 
It is known that the vascular tone is tightly controlled by complex neural, humoral and 
metabolic mechanisms. It is the primary target of the autonomic nervous system. A 
number of circulating hormones released from adrenal glands, kidneys and the central 
nervous system work on local tissues via their action on the vascular tone. Metabolic 
activity of local tissues can affect vascular tone through a number of metabolites.  
The contractility of vascular smooth muscles (VSMs) determines the vascular 
tone. It is known that smooth muscle contraction relies on a chain of biochemical 
reactions leading to the interaction of contractile filaments, where intracellular Ca2+ 
elevation serves as an initiating factor. Most vasoactive signals are transduced to a Ca2+ 
signal in the VSMs by a large number of receptors, ion channels and intracellular 
signaling molecules. Several key molecules have been found to integrate multiple sources 
of vasoactive signals and converge the information into the common Ca2+ signal in 
VSMs. The understanding of the molecular mechanisms for the actions of these key 
molecules would shed insight into the cellular basis of vascular tone regulation and 
provide the basis for designing effective therapeutical methods for hypertension, shock, 
and other cardiovascular disorders. 
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Ca2+ entry through voltage-gated Ca2+ channels (VDCCs) is one of the major 
sources of intracellular Ca2+ elevation in VSMs. The primary factor affecting VDCCs 
activity is membrane potential. Because membrane potentials are generated and 
controlled by K+ channels, the knowledge of how K+ channels change their activity in 
VSMs becomes critical for understanding vascular tone regulation.  
KATP channels are probably the most important K+ channels in vascular tone 
regulation. Previous studies in our laboratory have shown the vascular KATP channels are 
activated by hypercapnic acidosis. Others have demonstrated that the channels are 
activated by a change in intracellular ATP and ADP concentrations under metabolic 
stress. In addition to the above metabolic products, hormones and neurotransmitters 
tightly regulate vascular KATP channels. A numbers of vasodilating hormones and 
neurotransmitters activate KATP channels in vascular smooth muscles and various 
vasoconstrictors inhibit the channels. Thus, vascular KATP channels must integrate 
multiple vasoactive inputs and produce corresponding changes in vascular tone, affecting 
systemic blood pressure and local blood distribution.  
Accumulative experimental evidence indicates the PKA and PKC signaling 
pathways regulate channel activity by vasodilators and vasoconstrictors, respectively. It is 
assumed that the channel proteins are phosphorylated directly by these kinases. However, 
the molecular substrates for those protein kinases remain unknown, and other possibilities 
exist. For example, intermediate molecules downstream of the kinases may be involved, 
or changes in channel activity may be the result of alteration in membrane trafficking. 
The dissertation research was thus aimed at addressing the molecular basis of vascular 
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KATP channel regulation by PKA and PKC systems. A combination of 
electrophysiological, molecular biological, pharmacological and protein structural 
techniques were employed. Our data showed that the vascular KATP channels were 
directly phosphorylated by both kinases. By systemic analysis of the primary sequence as 
well as the tertiary structure of the channel proteins, potential mechanisms underlying the 
channel modulation by phosphorylations of the channel proteins were proposed. The 
mechanisms of the channel regulation discovered in this thesis provide fundamental 
information for the channel regulation by various vasoconstricting and vasodilating 
hormones and neurotransmitters that will eventually help in development of therapeutic 
strategies in the treatment and prevention of several cardiovascular diseases.  
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9. Material and Methods 
9.1. Cell culture  
Human embryonic kidney cells (HEK293, CRL-1573, Batch #2187595, ATCC, 
Rockville, MD) were chosen to express the KATP channels. The HEK293 cells were 
cultured as a monolayer in the MEM-E medium with 10% fetal bovine serum and 
penicillin/streptomycin added. Cultured at 37°C with 5% CO2 in the atmosphere, the cells 
were split twice weekly. The HEK293 cells were transfected using Lipofectamine2000 
(Invitrogen, Carlsbad, CA) with 1µg Kir6.1 and 3µg SUR2B per 35mm petri dish. To 
facilitate the identification of positively transfected cells, 0.5µg green fluorescent protein 
(GFP) cDNA (pEGFP-N2, Clontech, Palo Alto, CA) was added to the cDNA mixture. 
Cells were disassociated from the monolayer using 0.25% trypsin ~24hrs post-
transfection. A few drops of the cell suspension were added on to 5×5mm2 cover slips in 
a 35mm petri dish. The cells were then cultured for 24-48hrs before experiments 
9.2. Molecular biology 
Rat Kir6.1 (GenBank #D42145) and mouse SUR2B (GenBank #D86038) were 
used in studies in this thesis. Both cDNAs were cloned in the eukaryotic expression 
vector pcDNA3.1 and used for mammalian cell expression. The human β2-adrenergic 
receptor (ADRB2) (GenBank #NM_000024) was purchased from Origene (Rockville, 
MD).  
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Site-specific mutations were made using a site-directed mutagenesis kit 
(Stratagene, La Jolla, CA). Kir6.1-Kir6.2 chimeras were produced by overlap extension 
using PCR (pfu DNA polymerase, Stratagene) (Piao et al., 2001). The orientation of the 
constructs and correct mutations were confirmed with DNA sequencing. The constructs 
were expressed in HEK293. 
pMal vector (New England Biolabs) was used to express fusion proteins. The 
cDNAs of target peptides were amplified with PCR and inserted into pMal vector. The 
constructs were transfomed into protease-deficient E.coli BL21, in which MBP-fusion 
peptides were induced with 0.3mmol/L isopropylthiogalactoside for 2 hours. The MBP-
fusion peptides were purified using amylose resin according to the procedure by the 
provider (New England Biolabs).  
9.3. Artery rings 
Mesenteric arterial rings were obtained from Sprague-Dawley rats (250-350g) in 
accordance with the guidelines for the care and use of laboratory animals by Georgia 
State University. The rats were anesthetized by inhaling saturated halothane vapor 
followed by cervical dislocation. The mesenteric arteries were dissected free and transferred 
to ice-cold Krebs solution containing (in mM): NaCl 118.0, NaHCO3 25.0, KCl 3.6, 
MgSO4 1.2, KH2PO4 1.2, glucose 11.0, and CaCl2 2.5 bubbled with 5% CO2. The arteries 
were cut into 6-8 endothelium-intact rings of 2mm in length and stored in Krebs solution. 
Endothelium-denuded rings were also used in which the endothelium was removed by a 
rough plastic tube and tested by loss of response to acetylcholine. During the experiment, a 
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ring was mounted on a force-electricity transducer (Model FT-302, iWorx/CBSciences, 
Inc. Dover, NH) in a tissue bath. With a 0.8g preload, the ring was allowed to equilibrate in 
the tissue bath for 30min when the tension was reduced to ~0.6g. The tissue bath was filled 
with Krebs solution and perfused with 5% CO2 at 36°C. Arterial tone was measured as 
changes in isometric force. Only rings that showed a clear vasoconstriction response to 
1.0µM phenylephrine were used in the study. 
9.4. Dissociated vascular smooth muscle cells  
Acutely dissociated vascular smooth muscles were prepared with a two-step 
enzyme digestion. Mesenteric arteries were obtained as previously described, cut into 
small segments (1-2mm), and placed in a 5ml saline solution containing (in mM): NaCl 
140, KCl 5.4, MgCl2 1, CaCl2 0.1, HEPES 10 and D-glucose 10 at room temperature for 
10 min. The tissues were then placed in 1ml solution containing 20 units of papain 
(Worthington, New Jersey) and 1.25mg dithiothreitol (DTT). After incubation for 30min 
at 35°C, the tissue was washed once and then transferred to 1ml solution containing 440 
units of collagenase (CLS II, Worthington) and 1.25mg trypsin inhibitor (Sigma) for 
15min. After a thorough wash the tissue was moved to 1ml solution containing 20% fetal 
bovine serum and triturated with a fire polished Pasteur pipette to yield single smooth 
muscle cells. The cells were stored on ice and used within 8hrs. A drop of cells was 
placed in a 35mm tissue culture dish where the cells were allowed to attach to the 
surface. The cells that had typical smooth muscle morphology and did not show evident 
swelling or shrinkage were used for further studies. 
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9.5. Patch clamp experiments  
Patch clamp experiments were performed at room temperature as described 
previously. In brief, fire polished patch pipettes were made with 1.2mm borosilicate glass 
capillaries. Whole-cell recording was performed using single-cell voltage clamp with 
recording pipettes of 4-6MΩ. Current records were low-pass filtered (2kHz, Bessel 4–pole 
filter, –3dB), digitized (10kHz, 16–bit resolution), and stored on computer disk for later 
analysis using the Clampfit 6 and 9 software (Axon Instruments Inc.). The bath solution 
contained (in mM): KCl 10, potassium gluconate 135, EGTA 5, glucose 5, and HEPES 10 
(pH = 7. 4). The pipette solution contained (in mM): KCl 10, potassium gluconate 133, 
EGTA 5, glucose 5, K2ATP 1, NaADP 0.5 and HEPES 10 (pH = 7. 4), in which the free 
Mg2+ concentration was adjusted to 1mM using MgCl2. Since the variation of Cl‾ 
concentrations in solutions was rather small, the resulted liquid junction potential was less 
than 1mV according to the Henderson equation, and was thereby not corrected. Inside-out 
patches were performed with symmetric high K+ in the bath and pipette: KCl 10, potassium 
gluconate 135, EGTA 5, glucose 5, and HEPES 10 (pH = 7.4), with [Mg2+] adjusted to 
1mM using MgCl2. After formation of a giga-seal, the patch was excised and the 
intracellular side was exposed to bath solution. The holding potential was 0mV and a 
constant single voltage of -60mV was applied to the patch. All currents recorded from the 
inside-out patches were digitized in a higher sampling rate (20 kHz).  
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9.6. Phosphorylation sites prediction  
PKA and PKC phosphorylation sites were predicted using two online programs 
Kinasephos, (http: //kinasephos.mbc.nctu.edu.tw/) (Huang et al., 2005) and NetPhosK 
(http://www.cbs.dtu.dk/services/NetPhosK) (Blom et al., 2004). A serine or threonine 
was considered for further studies as a putative PKA site if there was an alkaline amino 
acid at the -2 or -3 position. A typical PKC site is serine or therionine followed by basic 
residues at +2 or +3 position.  
9.7. Western blot 
MBP-Kir6.1Cs with or without mutants were generated with the distal C-terminus 
segment (residues 346-420) of Kir6.1 fused to C-terminus of Maltose binding protein 
(MBP) using same methods detailed in above. The peptides were run in 10% SDS-page 
gel and transferred to PVDF membrane (Bio-Rad, Hercules, CA). Western blot was 
carried out using rabbit primary antibody against Kir6.1 C-terminus 
(KRNSMRRNNSMRRSN, corresponding to amino acid residues 382-396 of rat Kir6.1, 
Sigma, 1:2000) and secondary goat anti-rabbit IgG conjugated with alkaline phosphotase. 
The protein bands were depicted with bromochloroindolyl phosphate (BCIP) and nitro 
blue tetrazolium (NBT).  
9.8. In vitro phosphorylation  
In vitro phosphorylation was performed on SUR2B and Kir6.1Cs peptides fused 
to maltose-binding protein (MBP). Mutants were produced either using the site-directed 
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mutagenesis kit (Stratagene) or just using the templates with mutants in pcDNA3.1. The 
SUR2B fusion peptides were subsequently incubated with the catalytic subunit of PKA 
(cPKA, P2645 from Sigma) in the following reaction: 5μg fusion peptides in 5μl elution 
buffer (in mM) (NaCl 200, tris-HCl 30, EDTA 1, maltose 10, pH 7.4), 5μl of 5X reaction 
buffer (tris-HCl 125, EGTA 0.1, pH 7.5), 5μl Mg-ATP solution (MOPS 20, β-
glycerophosphate 25, EGTA 5, Na3VO4 1, DTT 1, MgCl2 75, ATP 0.5 and pH 7.2), 10 
units of cPKA in 10μl H2O and 1μl of 5μCi/μl of [32P-γ]-ATP (Perkin-Elmer, San 
Francisco, CA). After 1 hour 5μl of 5X protein loading buffer were added to each sample 
to terminate the reaction. The samples were then subjected to electrophoresis in 10% 
SDS-page gel, stained with Coomassie blue, and photographed. The gel was then fixed, 
dried. Autoradiography was carried out using a Fuji BAS 2500 Imaging Plate. This 
experiment was repeated twice. Same procedure was conducted for PKC in vitro 
phosphorylation on Kir6.1Cs peptides by replacing cPKAwith cPKC.  
9.9. Molecular modeling 
Modeling of the SUR2B_core was based on the crystal structure of SAV1866 
(PDB: 2HYD). The sequences of SAV1866 were aligned with both halves of the 
SUR2B_core (TM-NBD1 and TM-NBD2) using ClustalW. The atomic coordinates of 
amino acids, nucleotides and water molecules in the template (SAV1866) were 
transferred to the SUR2B_core model. The ADP molecule in first nucleotide binding 
pocket was replaced with ATP. The coordinates of ATP-binding Mg2+ and ADP-binding 
Mg2+ were obtained using the crystal structures of ABC transporters HlyB (PDB: 1XEF) 
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and TAP1 (PDB: 1JJ7), respectively. The linker regions between TMD1 and NBD1 
(residues 618-665), and between TMD2 and NBD2 (residues 1290-1309) were modeled as 
surface loops in the structure. The linker between NBD1 and TMD2 (residues 914-975) 
was omitted from the model due to lack of a template. Energy minimization was 
performed using 1000 steps of conjugate gradients optimization with the latest AMMP 
potential set (version tuna) (Chen et al., 2004). The model was viewed with PyMOL 
(http://pymol.sourceforge.net/). 
9.10. Molecular dynamics simulation 
Molecular dynamics (MD) simulations were carried out to study the 
conformational change in the NBD2-ICL2 interface. The SUR2B_core model contained 
many hydrophobic transmembrane segments that that would require a very large 
molecular dynamics simulation including the lipid bilayer. Therefore, we constructed two 
models containing NBDs and an extended segment of ICL2 (residues 500-512) with and 
without a phosphate group linked to atom Og of Ser1387. Seven thousand and five 
hundred H2O were added to the model molecules to ensure an aqueous environment. 
Additional ions were added to neutralize the total charge of the protein. No screening 
dielectric term or bulk solvent correction was included. A constant dielectric of one was 
used. The amortized fast multipole algorithm in AMMP was used for the long-range 
terms in the non-bonded and electrostatic potentials so that no-cutoff radius was 
employed (Harrison, 2003). Simulations were performed with a constant NVT (number, 
volume and time) ensemble corresponding to a pressure about 1 atm with classical 
 
 
38
molecular mechanics MD program AMMP (Harrison & Weber, 1994; Chen et al., 2004). 
The temperature was set at 310K. One thousand frames, one for each picosecond, were 
logged over 1-ns MD run. The mode structures which represent the most frequent 
position of each atom (Chen et al., 2004) and the RMSDs of Cαs of each residue were 
calculated over 1000 frames.  
9.11. Chemicals  
Chemicals used in my studies were purchased from Sigma (St. Louis, MO) unless 
otherwise stated. All chemicals were prepared as high concentration stocks in double 
distilled H2O or DMSO, and were diluted in the recording solution to experimental 
concentrations immediately before usage. In cases where DMSO was used, its concentration 
was maintained at less than 0.1% in the experimental solutions. This concentration of 
DMSO does not affect the Kir6.1/SUR2B channel. Isoproterenol, glibenclamide, pinacidil 
and forskolin were applied to cells using a perfusion system. Adrenergic β1 and β2 
antagonists were administrated at least 2min prior to and during the isoproterenol exposure. 
PKA inhibitors RP-cAMP was included in the pipette solution (200μM) and added to the 
perfusion solution (100μM). PKA inhibitory peptide (PKI5-24, 10μM) was applied to the 
pipette solution. To avoid ATP degradation, all ATP containing solutions were made 
immediately before experiments and used no longer than 4hrs.  
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9.12. Data analysis 
Data are presented as means ± s.e. Differences in means were tested with the 
ANOVA or Student t-test and were accepted as significant if P ≤ 0. 05. 
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10. Result 1: PKA Phosphorylation of SUR2B Subunit Underscores 
Vascular KATP Channel Activation by Β-Adrenergic Receptors  
 
 
 
 
 
 
 
 
 
 
 
 
Publication: Yun Shi, Zhongying Wu, Ningren Cui, Weiwei Shi, Yang Yang, Xiaoli 
Zhang, Asheebo Rojas, Binh T Ha, Chun Jiang. (2007) Am J Physiol. 293(3), R1205-14 
 
Note: In this paper, Yun Shi did ~80% of the work, including experimental design, 90% 
of patch experiments, 60% of DNA mutations preparation, 80% of fusion-protein 
construction and purification, and in vitro phosphorylation. Zhongying Wu and Nga Ta 
(her name is in acknowledgement) helped prepare cDNAs and mutations. Dr. Ningren 
Cui did most of mesenteric ring experiments. Weiwei Shi, Yang Yang and Xiaoli Zhang 
helped in patch clamp experiments. Binh T Ha contributed to setting up protein 
purification system. Asheebo Rojas helped in setting-up in vitro phosphorylation assay.  
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10.1. Abstract 
KATP channels are activated by several vasodilating hormones and 
neurotransmitters through the PKA pathway. Here we show that phosphorylation at 
Ser1387 of the SUR2B subunit is critical for the channel activation. Experiments were 
performed in HEK293 cells expressing the cloned Kir6.1/SUR2B channel. In whole-cell 
patch, the Kir6.1/SUR2B channel activity was stimulated by isoproterenol via activation 
of β2 receptors. This effect was blocked in the presence of inhibitors for adenylyl cyclase 
or PKA. Similar channel activation was seen by exposing inside-out patches to the 
catalytic subunit of PKA. Since none of the previously suggested PKA phosphorylation 
sites accounted for the channel activation, we performed systematic mutational analysis 
on Kir6.1 and SUR2B. Two serine residues (Ser1351, Ser1387) located in the NBD2 of 
SUR2B were critical for the channel activation. In vitro phosphorylation experiments 
showed that Ser1387 but not Ser1351 was phosphorylated by PKA. The PKA-dependent 
activation of cell-endogenous KATP channels was observed in acutely dissociated 
mesenteric smooth myocytes and isolated mesenteric artery rings where activation of 
these channels contributed drastically to the isoproterenol-induced vasodilation. Taken 
together, these results indicate that the Kir6.1/SUR2B channel is a target of β2 receptors, 
and the channel activation relies on PKA phosphorylation of SUR2B at Ser1387 in HEK 
cells.  
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10.2. Introduction 
Vascular KATP channels are activated by PKA. Blockade of PKA signaling 
pathway eliminates the channel modulation by several vasodilators such as adenosine, 
calcitonin gene-related peptide and epoxyeicosatrienoic acids and abolishes their effects 
on vascular tone (Quayle et al., 1994; Kleppisch & Nelson, 1995; Wellman et al., 1998; 
Ye et al., 2005). It is known that the PKA signaling pathway can be activated by β 
adrenergic receptors (β-ARs). Stimulation of β-ARs hyperpolarizes VSMs leading to 
vasodilation (Guimaraes & Moura, 2001; Johnson, 2006).  
Although both β1 and β2 receptors may be involved, the β2 receptor is known to 
play a major role. Mice with β2 receptor gene knockout develop hypertension during 
exercise or with adrenaline challenges (Chruscinski et al., 1999). Abnormalities in β 
adrenergic responses are seen in rats with spontaneous hypertension (Goto et al., 2001). 
In humans, single nucleotide polymorphisms in the β2 receptor gene are associated with 
increased vasoconstrictor sensitivity and stage-2 hypertension (Dishy et al., 2004; Ge et 
al., 2005). Pharmacologic studies have suggested that K+ channels contribute to the β-AR 
mediated vasodilation, especially KATP channels (Randall & McCulloch, 1995; Chang, 
1997; Ming et al., 1997; Sheridan et al., 1997; Hein et al., 2004).  
Although the PKA-dependent activation of vascular KATP channels has been 
shown in previous studies, questions as to how PKA stimulation leads to the channel 
activation, whether the channels are directly phosphorylated by PKA, whether the Kir6.1, 
SUR2B or both are targets of PKA phosphorylation are still unclear. To address these 
questions, we performed studies on cloned Kir6.1/SUR2B channel. Our data suggest that 
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phosphorylation of SUR2B subunit underscores the channel activation by β adrenergic 
receptor signaling pathway in HEK cells. 
10.3. Results 
10.3.1. Baseline Kir6.1/SUR2B channel activity 
The Kir6.1/SUR2B channel was transiently co-expressed with GFP in HEK293 
cells. Whole-cell voltage clamp was performed on GFP-positive cells. Without any 
treatment the currents remained small or were slightly increased in a period of 8-10min. 
Strong current activation was seen when the cell was exposed to 10µM pinacidil. The 
pinacidil-activated currents were strongly inhibited by 10µM glibenclamide. The currents 
did not show clear inward rectification (Fig. 10-1A). These characteristics are consistent 
with the Kir6.1/SUR2B currents reported previously (Yamada et al., 1997; Satoh et al., 
1998). HEK293 cells transfected with the expression vector alone were used as negative 
control, in which small inward rectifier currents were seen. The currents were insensitive 
to pinacidil and glibenclamide (Fig. 10-1B).  
 
Figure 10-1. Kir6.1/SUR2B channels expressed in HEK293 cells.  
A. Whole-cell currents were recorded from a cell transfected with Kir6.1/SUR2B. 
Symmetric concentrations of K+ (145mM) were applied to both sides of cell membranes. The cell 
was held at 0mV, and pulse voltages from –120 to 80mV with a 20mV increment were applied. 
The current amplitude increased in response to isoproterenol (Isop, 100nM). The isoproterenol-
activated currents were further activated by pinacidil (Pin, 10μM) and inhibited by glibenclamide 
(Glib, 10μM). B. Currents recorded from another cell transfected with the expression vector alone 
were insensitive to isoproterenol, pinacidil and glibenclamide. C. The time course for the 
Kir6.1/SUR2B channel modulation. Whole-cell currents were recorded with a holding potential at 
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0mV and command pulses of –80mV in every 3 seconds. After whole-cell configuration was 
formed, the cell was perfused with extracellular solution for a 4-6min baseline recording. Note 
that the baseline record was shortened in the figure. The currents were strongly activated by 
isoproterenol, and the maximum activation was reached in 3-4min of the exposure. The currents 
were inhibited by glibenclamide (10μM) and further activated by pinacidil (10μM). The lower 
panel shows individual currents produced by a single command pulse. D. In the presence of 
glibenclamide, isoproterenol failed to activate the Kir6.1/SUR2B channel. 
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10.3.2. Activation of the Kir6.1/SUR2B channel by β2 receptor stimulation 
The β2-AR was over-expressed in HEK293 cells together with Kir6.1 and 
SUR2B. The β-AR agonist isoproterenol was applied to the cell following stabilization of 
the baseline currents for 4-6 min. The isoproterenol exposure activated K+ currents that 
were sensitive to both pinacidil and glibenclamide. We found that without β2-AR 
transfection, the Kir6.1/SUR2B currents were still activated by isoproterenol. This 
observation is consistent with the previous finding that β2–AR is endogenously expressed 
in HEK293 cells (Daaka et al., 1997; Smith et al., 2002). Therefore, further experiments 
were conducted in the HEK293 cells without exogenous β-ARs. The currents activated 
by isoproterenol were further activated by pinacidil and inhibited by glibenclamide (Fig. 
10-1A, C). The channel activation was totally eliminated in the presence of 10µM 
glibenclamide (Fig. 10-1D) and not seen in cells transfected with the expression vector 
alone (Fig. 10-1B).  
After currents were normalized between maximum channel inhibition by 10µM 
glibenclamide and maximum activation by 10µM pinacidil, the baseline currents 
averaged 6.9±1.5% (n=27) of the maximum channel activity. Isoproterenol (100nM) 
increased the currents to 42.6±3.0% (n=8). The effect showed clear concentration 
dependence (Fig. 10-2). Evident current activation occurred with 1nM isoproterenol, and 
the maximum effect was reached with 100nM. The EC50 was 4.3nM with a Hill 
coefficient of 1.4 (Fig. 10-2).  
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Figure 10-2. Concentration-dependent activation of Kir6.1/SUR2B currents by 
isoproterenol.  
The effect of isoproterenol was measured and normalized between the maximum channel 
inhibition by 10μM glibenclamide and maximum channel activation by 10μM pinacidil. Baseline 
currents with no isoproterenol were 7.4±1.9% (n=18) of full channel activation by pinacidil. 
Evident activation of the Kir6.1/SUR2B currents was seen with 1nM isoproterenol (11.5±3.2%, 
n=4), 10nM (34.2±4.1%, n=6) and the maximum activation was reached with 100nM (42. 6±3. 
0%, n=8). Further increase in isoproterenol concentration had no further activation, 1μM 
(43.8±5.7%, n=6) and 10μM (39.4±5.7%, n=7). The concentration-current relationship was 
described using the Hill equation y = 0.074+0.355/(1+(EC50/[Isop])h), where y is normalized 
Kir6.1/SUR2B currents, [Isop] is isoproterenol concentration, EC50 (4.3nM) is the Isop 
concentration for 50% channel activation, and h (1.4) is the Hill coefficient.  
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To identify the receptor subtype involved we applied specific β-AR antagonists to 
the cells 2min prior and during the administration of isoproterenol. The isoproterenol 
effect was almost completely blocked by β2–AR antagonist ICI-118551 (100nM), 
whereas β1–AR antagonist atenolol (1μM) had no effect (Fig. 10-3A-C). These results 
thus indicate that isoproterenol activates the Kir6.1/SUR2B channel through endogenous 
β2–AR in HEK293 cells. 
10.3.3. PKA dependence 
The Kir6.1/SUR2B activation by isoproterenol was blocked when 8-(4-
chlorophenylthio) adenosine-3′, 5′-cyclic monophosphorothioate RP-isomer (RP-cAMP), 
a PKA inhibitor, was applied in both the pipette solution (200μM) and the perfusion 
solution (100μM) (Fig. 10-3C, D). Similar blockade was seen in the presence of the 
specific PKA inhibitory peptide (PKI5-24, 10μM) added in pipette solution, suggesting 
that PKA is involved in the activation of the channel by isoproterenol (Fig. 10-3C, E).  
 
 
Figure 10-3. Dissection of signal pathway for Kir6.1/SUR2B channel activation by 
isoproterenol.  
A. In the presence of β2 receptor antagonist ICI-118551 (100nM), isoproterenol had very 
little effect on the Kir6.1/SUR2B currents. B. With β1 antagonist atenolol (1μM), isoproterenol 
remained to activate the Kir6.1/SUR2B currents. Note that β-AR antagonists were perfused to 
cells 5min before and during the isoproterenol exposure. C. Currents were normalized to pinacidil 
and glibenclamide effects. Open bar, baseline current; black bar, isoproterenol; hatched bar, 
forskolin (FSK). 2Deox-ATP, 2’,5’-dideoxyadenosine-3’-triphosphate; PTX, pertusis toxin. ***, 
P<0.001; **, P<0.01; *, P<0.5 (n = 5 to 14). D. RP-cAMP, a potent PKA inhibitor, was applied in 
both pipette solution (200μM) and perfusion solution (100μM). The currents activation by 
isoproterenol was almost completely blocked. E. Similar blockage of the channel activation was 
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observed with a PKA inhibitory peptide (PKI5-24, 10μM) in the pipette solution. F. The effect of 
cAMP (100μM) in pipette solution on the Kir6.1/SUR2B currents. After formation of whole-cell 
configuration, the current amplitude gradually increased and became plateaued at ~40% of the 
maximum activation by pinacidil in ~5min. Application of isoproterenol did not produce further 
activation of the Kir6.1/SUR2B currents.  
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Since activation of Gs stimulates adenylyl cyclase, we studied the effect of 
forskolin, a potent adenylyl cyclase activator, on the Kir6.1/SUR2B currents. Exposure to 
10μM forskolin activated the channel to almost the same degree as isoproterenol (Fig. 10-
3C). The forskolin-activated currents also showed identical characteristics to those 
activated by isoproterenol. When the adenylyl cyclase inhibitor, 2’,5’-dideoxyadenosine 
3’-triphosphate (2deox-ATP) was included in the pipette solution, the channel activation 
by isoproterenol was diminished to 21.3±7.2% with 2µM (n=4) and 21.9±4.9% with 
10µM (n=4), respectively. Since no difference was seen in these two concentrations, they 
were pooled together to compare with the experimental control. We found that these 
values were significantly lower than those of the control (P<0.01, n=14; Fig. 10-3C), 
suggesting that Gs-activated adenylyl cyclase is involved.  
The Kir6.1/SUR2B currents were gradually activated when 100μM cyclic AMP 
(cAMP) was included in pipette solution (Fig. 10-3C, F). The currents averaged 
42.8±5.4% (n=5) of the total currents activated by 10µM pinacidil. Under such a 
condition, application of 100nM isoproterenol produced no further increase in the current 
amplitude (Fig. 10-3C, F).  
It is known that persistent β2-AR stimulation switches the intracellular signaling 
from a Gs cascade to Gi. To determine whether Gi also affects the Kir6.1/SUR2B channel 
activation by isoproterenol, we pretreated the cells overnight with pertusis toxin, a potent 
Gi inhibitor. Such a treatment had no effect on the Kir6.1/SUR2B channel activation by 
10µM isoproterenol (Fig. 10-3C), indicating that Gi is not involved in the Kir6.1/SUR2B 
activation by isoproterenol.  
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To further demonstrate the PKA dependence, experiments were performed in 
excised inside-out patches. In the absence of nucleotide, the channels were mostly closed. 
Significant increase in the current amplitude was seen when the patches were exposed to 
perfusion solution containing Mg2+ and nucleotide, i.e., 1.0mM free Mg2+, 0.5mM ADP 
and 1.0mM ATP (Fig. 10-4), consistent with previous reports (Satoh et al., 1998; Wang 
et al., 2003). When the internal membrane of inside-out patches was exposed to the 
catalytic subunit of PKA in the presence of the same concentrations of Mg2+, ADP and 
ATP, the Kir6.1/SUR2B channel was further activated (Fig. 10-4). Such channel 
activation was mediated by the augmentation of the open-state possibility (NPo) with no 
evident effect on the single-channel conductance. These data thus indicate that the 
channel activation is independent of other soluble cytosolic factors.  
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Figure 10-4. Augmentation of Kir6.1/SUR2B channel activity by the catalytic subunit of 
PKA.  
A. The Kir6.1/SUR2B currents were recorded in an inside-out patch obtained from a 
HEK cell with a holding potential of -60mV and equal concentrations of K+ applied to both sides 
of the patch membranes. The channel activity was low in the baseline. Exposure of the internal 
patch membrane to 1.0mM ATP and 0.5mM ADP led to activation of the channels that showed a 
unitary conductance ~35pS (lower panel). The channels were further activated with an 
application of cPKA (100U/ml) to the internal solution in the presence of same concentrations of 
ATP and ADP. B. Summary of the experiment. Channel activity (NPo) was normalized to the 
level of pinacidil (Po/Po(Pin)). The channel activity was rather low at baseline, increased markedly 
with ADP/ATP, and was further augmented with addition of cPKA. ***, P<0.001 (n=9 patches).  
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10.3.4. PKA phosphorylation sites 
A previous study suggested three PKA phosphorylation sites in the 
Kir6.1/SUR2B channel, i.e., Ser385 in the Kir6.1 subunit, and Thr633 and Ser1465 in the 
SUR2B (Quinn et al., 2004). To further understand the KATP channel activation by β–
ARs, we mutated these three residues either individually or jointly. The 
Kir6.1_S385A/SUR2B mutant, in which the Ser385 was mutated to alanine, was 
activated by 100nM isoproterenol (48.7±3.0%, n=10) and 10µM forskolin (39.2±2.3%, 
n=6) to almost the same degree as the wild-type (WT) channel (Fig. 10-5A, D). The 
channel was still activated when the Ser385 was mutated to asparagine or glutamate, 
though to a less degree in the S385E mutation (Fig. 10-5D). A channel with all three 
residues mutated (Kir6.1_S385A/SUR2B_T633A_S1465A or 3AA) responded to 
isoproterenol (44.6±4.3%, n=6) and forskolin (42.0±3.0%, n=10) and showed no 
significant difference from the WT channel under our experimental condition (Fig. 10-
5B, D). Besides Ser385, Thr234 is another potential PKA site as suggested by its 
counterpart residue (Thr224) in Kir6.2 (Lin et al., 2000). Neither Kir6.1_T234A nor 
Kir6.1_T234N mutation affected the channel activation by forskolin (Fig. 10-5C, D).  
Since none of the PKA sites suggested by previous studies seems to be involved 
in the activation of the Kir6.1/SUR2B channel by isoproterenol, we performed systematic 
mutational analysis on both subunits. In the Kir6.1 subunit, nine other residues were 
predicted based on PKA consensus sequences (Blom et al., 2004; Huang et al., 2005). 
Site-specific mutations of eight of them had no effect on the channel activation by 
forskolin, while mutation of Thr190 to either alanine or asparagine failed to produce 
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pinacidil-sensitive currents (Fig. 10-5D), consistent with a previous observation that the 
T190A-mutant channel is non-functional (Thorneloe et al., 2002).  
 
 
Figure 10-5. Mutation on potential PKA sites.  
A. With a mutation of Ser385 to alanine, the Kir6.1_S385A/SUR2 currents were strongly 
activated by forskolin. B. The channel was still activated when three potential PKA sites, i.e., 
Ser385 in the Kir6.1, and Ser1465 and Thr633 in the SUR2B subunit, were all mutated to alanine. 
C. The Thr234 mutation on Kir6.1 did not abolish the channel activation by forskolin. D. 
Summary of mutagenesis analysis of potential PKA sites. All mutations were constructed on 
Kir6.1 except 3AA in which Ser385 in Kir6.1, and Ser1465 and Thr633 in SUR2B were mutated 
to alanine. *, P<0.05 
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Figure 10-5 
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Subsequently, we performed systematic mutational analysis of the SUR2B 
subunit. Ten PKA consensus sequences were found in the NBD1 and NBD2. Each site 
was mutated to alanine. All of these mutants expressed functional currents similar to the 
WT channel, i.e., small baseline currents stimulated by pinacidil and inhibited by 
glibenclamide (Table 10-1). Two residues (Ser1351, Ser1387) were found to be critical. 
Mutation of either residue to alanine caused severe disruption of the channel activation 
by isoproterenol and forskolin that was independent of the pinacidil effect (Fig. 10-6A, B, 
E and Table1). The effect of cAMP dialysis on Kir6.1/SUR2B_S1387A was also tested 
(Fig. 10-6D, E). With the mutation, cAMP failed to activate the channel. Ser1351 is 
located in the NBD2 immediately following the Walker A sequence, and 36 residues 
away lies the Ser1387. Two serine residues are found in the NBD1 at corresponding 
locations, i.e., Ser710 and Ser748 (Fig. 10-6F). Mutation of either residue did not affect 
the channel activation by forskolin (Fig. 10-6C, E). Mutation of the remaining potential 
PKA sites had no effect on the channel sensitivity to forskolin either (Fig. 10-6E).  
To address the question whether these two serine residues in SUR2B can be 
phosphorylated by PKA, we performed in vitro phosphorylation experiments on SUR2B 
peptides (containing residues 1308-1399 of SUR2B) with and without the S1351A and/or 
S1387A mutation. The peptides were fused to MBP, and expressed in bacteria. After 
purification with the amylose affinity column, these peptides were subjected to in vitro 
phosphorylation in the presence of the catalytic subunit of PKA and [32P-γ]-ATP. Strong 
phosphorylation was seen in the WT peptide and the peptide containing the S1351A 
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mutation. The peptides with the S1387A mutation either alone or jointly with the S1351A 
mutation were failed to be phosphorylated (Fig. 10-7A).  
 
 
Table 10-1. The effect of forskolin on Kir6.1/SUR2B and SUR2B mutants.  
Baseline Forskolin Glib Pinacidil n 
WT 0.64±0.34 1.89±0.60 0.39±0.11 4.08±0.98 7 
T633A 0.69±0.27 3.58±1.59 0.34±0.11 6.63±2.71 5 
S710A 0.76±0.12 3.65±0.82 0.22±0.05 9.04±1.96 5 
S745A 0.64±0.09 1.59±0.30 0.33±0.07 3.92±0.71 9 
S748A 0.57±0.10 2.41±0.54 0.24±0.09 5.76±0.66 5 
T782A 0.78±0.26 1.79±0.70 0.34±0.05 4.50±1.67 5 
S1347A 0.71±0.30 1.96±0.60 0.20±0.08 4.56±0.81 6 
S1351A 0.37±0.15 0.48±0.15** 0.28±0.14 3.58±0.67 5 
S1351N 0.29±0.12 0.25±0.11** 0.23±0.11 3.44±0.69 4 
S1387A 0.26±0.07 0.48±0.16** 0.16±0.06 4.99±1.60 6 
S1464A 0.88±0.46 5.88±1.91 0.50±0.24 11.26±2.49 5 
S1465A 0.94±0.15 1.79±0.46 0.68±0.19 2.81±0.87 5 
 
All of the mutants showed small baseline currents (nA) similar to the wilt-type (WT) 
Kir6.1/SUR2B channel. The currents were activated by pinacidil and inhibited by glibenclamide 
to a similar degree. The currents of the Ser1351 and Ser1387 mutants appeared to be smaller at 
the baseline, but they were not significantly different from the WT. After exposure to forskolin, 
the Ser1351 and Ser1387 mutants had smaller currents than the WT and other mutants (** P<0. 
01). The normalized currents with forskolin exposure were shown in Fig. 10-6E.  
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Figure 10-6. Identification of PKA phosphorylation sites in SUR2B.  
Mutants were co-expressed with WT Kir6.1 in HEK cells. A,B. Site-specific mutation of 
Ser1387 and Ser1351 in SUR2B abolishes the channel activation by 10µM forskolin. C. Similar 
mutation at Ser710 had no effect on forskolin sensitivity. D. Intracellular dialysis of cAMP 
(100μM in pipette solution) showed only modest stimulation of the S1387A currents, in sharp 
contrast to the WT channel shown in Fig. 10-3F. E. In comparison to WT, mutations of Ser1351 
and Ser1387 caused a loss of channel activation by forskolin. The Ser1351 and Ser1387 mutants 
failed to be activated by isoproterenol either (**, P<0. 01, n = 4 to 6). F. Alignment of amino acid 
sequences around Walker A in NBD1 (upper) and NBD2 (lower). Boxed are Walker A sequences. 
Ser1351 and Ser1387 are bold and the proposed PKA consensus sequence underlined. Similar 
sequences are seen in NBD1, while both Ser710 and Ser748 are not functional PKA sites.  
 
 
 
 
 
   Forskolin Pin Glib 
 Forskolin Pin Glib 
Forskolin Glib Pin  
  Isop Pin Glib 
A 
B 
C 
D 
2 nA 
1 min 
 
 
Kir6.1 / SUR2B_S1387A 
Kir6.1 / SUR2B_S1351A 
Kir6.1 / SUR2B_S710A 
Kir6.1 / SUR2B_S1387A  
 cAMP stabilization 
 
07610005 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
I /
 I p
in
ac
id
il
WT WT
T6
33
A
S7
10
A
S7
45
A
S7
48
A
T7
82
A
S1
34
7A
S1
35
1A
S1
35
1A
S1
35
1N
S1
38
7A
S1
38
7A
S1
38
7A
_c
AM
P
S1
46
4A
S1
46
5A
Forskolin 
Isop 
 I 
/ I
Pi
n 
 
**
VGQVGCGKSSLLLAILGEMQTLEGKVYWNNVNESEPSFEATRSRSRYSVAYA 
 
CGRTGSGKSSLSLAFFRMVDIFDGKIVIDGIDISKLPLHTLRSRLSIILQD 
 
701 NBD1 752
 
 
 
 
1341 NBD2 1392 
D
 
 
E 
 
 
58
Figure 10-7. Characterization of Ser1387 in PKA phosphorylation.  
A. A short peptide in SUR2B (residues 1308 - 1399) was fused to C-terminus of MBP. 
Site-specific mutations of S1351A and/or S1387A were created on the peptide. After purification 
with amylose-affinitive beads, correct peptides were revealed in SDS-PAGE gel (left). A 
50kDolton band is seen in Lanes 1 through 4 containing WT, S1351A, S1387A, and 
S1351A/S1387A double mutations, respectively. Lane 5, MBP protein. Another band of 
~100kDolton is also seen suggesting dimerization of the fusion peptides. Autoradiograph with 
[32P-γ]-ATP after an 8-hour exposure (right) showed positive labeling of the WT and S1351A but 
not the S1387A, and S1351A/ S1387A peptides and the control MBP. B, C. In comparison to the 
WT channel, the S1387A mutant was slightly activated by the catalytic subunit of PKA (n=5). 
Note that the S1387A currents with cPKA exposure were smaller than the baseline level the WT 
channel.  
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Figure 10-7 
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In excised patches, the S1387A channel had a rather low baseline activity. 
Channel activity increased with an exposure to 0.5mM ADP and 1.0mM ATP. Under this 
condition, the channel activity was slightly stimulated by the catalytic subunit of PKA 
(100U/ml) (Fig. 10-7B, C). Although the S1387A mutation did not completely eliminate 
the channel activation, the channel activity remained lower than the basal activity of the 
WT channel (Fig. 10-7C). These results are consistent with our observations in whole-
cell recordings, indicating that the Ser1387 is likely to be a PKA site (Table 1 and Fig. 
10-6A).  
10.3.5. Activation of vascular KATP channels by isoproterenol 
In acutely dissociated VSMs obtained from rat mesenteric arteries, inward K+ 
currents were activated with an exposure to 100 nM isoproterenol (Fig. 10-8A). The 
isoproterenol-activated currents averaged 35.4±7.3% (n=6) of the total currents activated 
by 10μM pinacidil, and showed a nearly identical pattern to the Kir6.1/SUR2B currents 
expressed in HEK cells (Fig. 10-8A, B). The same concentration of isoproterenol failed 
to produce significant current activation when the pipette solution contained PKI5-24 
(Fig. 10-8B). These results consistent with those obtained from the Kir6.1/SUR2B 
channel suggest that the VMS-endogenous KATP channels are activated by PKA 
phosphorylation.  
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Figure 10-8. Effects of isoproterenol on vascular smooth muscles.  
A. Whole-cell currents were recorded from a smooth myocyte acutely dissociated from 
the mesenteric artery. Exposure to 100nM isoproterenol activated the currents that were further 
activated by 10µM pinacidil. The lower panel shows current traces recorded with a single voltage 
protocol. B. The isoproterenol-activated currents were not seen in the presence of PKI5-24 (PKI, 
10μM) in the pipette solution. C. In a mesenteric ring, phenylephrine (PE) produced 
vasoconstriction that was reversed by isoproterenol. Such vasorelaxation effects were markedly 
attenuated in the presence of a β2-AR antagonist ICI-118551 (ICI). Note that pinacidil can 
completely relax the mesenteric ring. D. Summary of vasorelaxation effects of isoproterenol on 
the PE-induced vasoconstriction with and without ICI on endothelium-intact rings (n=7). E. 
Similar vasorelaxation was observed in endothelium-denuded rings (n=6). *, P<0.05; **, P<0.01; 
***, P<0.001. 
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In endothelium-intact mesenteric rings, phenylephrine produced vasoconstriction. 
Such vasoconstriction could be dose-dependently reversed by isoproterenol, and was 
completely eliminated by pinacidil (Fig. 10-8C). The vasorelaxation effect of 
isoproterenol was significantly attenuated with a pretreatment with the β2–AR antagonist 
ICI-118551 (100nM) (Fig. 10-8C, D). Similar phenomenon was found in endothelium-
denuded mesenteric rings (Fig. 10-8E). These results suggest that the isoproterenol-
induced vasodilation involves β2–AR and requires the activation of VSM-endogenous 
KATP channels, consistent with our observations in the heterologous expression system 
and acutely dissociated vascular smooth myocytes. 
10.4. Discussion 
10.4.1. PKA mediates Kir6.1/SUR2B channel activation by isoproterenol.  
Our results in HEK cells have shown that the Kir6.1/SUR2B channel is a down-
stream target of β2-ARs. The channel regulation results from activation of the Gs – 
adenylyl cyclase – cAMP– PKA pathway. Two serine residues in the NBD2 are critical 
for the channel activation by isoproterenol and forskolin. One of the residues indeed can 
be phosphorylated by PKA in vitro. PKA stimulation could explain activation of VSM-
endogenous KATP channels and relaxation of mesenteric arteries by isoproterenol.  
The Kir6.1/SUR2B channel activation by isoproterenol is mediated by the β2-
ARs–Gs–adenylyl cyclase – cAMP – PKA pathway in HEK cells, and this transduction 
cascade may also exist in VSMs. β2-AR regulation of KATP channels in VSMs is 
consistent with existing experimental evidence showing that the β2-ARs are expressed in 
 
 
63
vascular smooth muscles, β2-AR antagonism affects vascular tone, and β2-AR gene 
targeting causes disruption of vascular regulation and hypertension (Chruscinski et al., 
1999; Goto et al., 2001; Guimaraes & Moura, 2001; Dishy et al., 2004; Ge et al., 2005; 
Johnson, 2006). In agreement with previous findings for cell-endogenous KATP channels 
(Chang, 1997; Wellman et al., 1998; Ye et al., 2005), Kir6.1/SUR2B channel activation 
by isoproterenol in HEK cells relies on PKA activity, as the PKA inhibitors RP-cAMP 
and PKI5-24 block channel activation. Activation of adenylyl cyclase is also necessary, 
since intracellular dialysis of cAMP and activation of adenylyl cyclase by forskolin 
augments the Kir6.1/SUR2B currents to the same extent as isoproterenol. It was 
previously shown that in HEK cells, the β2-ARs can be phosphorylated by PKA leading 
to a switch to Gi cascade (Daaka et al., 1997). Our results suggest that Gi is not a key 
player in Kir6.1/SUR2B activation by isoproterenol, as the channel activation remains 
following Gi inhibition by a pretreatment of HEK cells with pertusis toxin. Beside the 
PKA system, the exchange proteins directly activated by cAMP (Epacs) have been 
reported to mediate the inhibitory effects of cAMP on the pancreatic KATP isoform (Light 
et al., 2002; Kang et al., 2006). Glucagon-like peptide-1 raises cAMP concentrations that 
initiate binding of Epacs to SUR1, which inhibits the Kir6.2/SUR1 channel (Light et al., 
2002). Such a PKA-independent effect of cAMP does not seem to play a significant role 
in the activation of Kir6.1/SUR2B, as the channel activation is abolished by PKA 
inhibitors as well as mutation of the PKA site in SUR2B.  
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10.4.2. Why can’t we repeat the others’ sites?  
A previous study has shown that the Kir6.1/SUR2B channel is modulated by 
PKA, and the channel activation was due to direct phosphorylation of the channel 
proteins at three sites (one in Kir6.1 and two in SUR2B) (Quinn et al., 2004). We have 
examined these residues in the present study. However, our results suggest that in our 
system these three residues do not seem to play a role in the Kir6.1/SUR2B channel 
activation by PKA in the presence of physiological levels of nucleotides, as mutations of 
these residues did not show significant effect on the channel activation by isoproterenol 
and forskolin. The different observations are probably due to experimental conditions. 
The Kir6.1/SUR2B currents were recorded in the presence of 0.5mM UDP in the study 
by Quinn et al. (Quinn et al., 2004) in comparison to 0.5mM ADP in the present study. 
Because the Kir6.1/SUR2B channel is strongly activated by UDP, forskolin only 
increased the whole-cell current amplitude by ~50% in their study (Quinn et al., 2004), 
whereas the currents is augmented by ~500% by isoproterenol or forskolin in the present 
study. It is noted that cell lines from different sources may have different intracellular 
signaling cascades. Such a difference in HEK cells has been reported previously (Clark & 
Baro, 2007), contributing to different cellular responses to a give stimulus.  
10.4.3. What is the explanation for Ser1351 mutations? 
In the present study, we have systematically mutated all 11 consensus PKA sites 
in the Kir6.1 subunit. Ten of them do not seem to be functionally phosphorylated by 
PKA, as mutations to non-phosphorylatable residues do not affect the channel activation 
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by forskolin. The role of the other residue Thr190 remains uncertain as channels with a 
mutation at this position were non-functional (Thorneloe et al., 2002) (Fig. 10-5D).  
In the SUR2B subunit, our systematic mutational analysis revealed two serine 
residues, i.e., Ser1351 and Ser1387 that are both located in the NBD2. Mutation of either 
one abrogates Kir6.1/SUR2B channel activation by isoproterenol and forskolin. In vitro 
phosphorylation of a purified fusion peptide of SUR2B suggests that Ser1351 is not 
phosphorylated by PKA. A straightforward explanation of the results is that the Ser1351 
may be involved in ADP binding on the Walker-A motif. Its mutation thus affects ADP 
binding. It is also possible that the isolated peptide may have lost its normal folding and 
failed to be phosphorylated in vitro. Interestingly, a corresponding serine is also found in 
SUR1 (Ser1387), its mutation (SUR1_S1387F) and deletion (SUR1_ΔS1387) have been 
found in patients with congenital hyperinsulinism (Aguilar-Bryan & Bryan, 1999; 
Thornton et al., 2003; Stanley et al., 2004). In the current study, a replacement of this 
serine residue (SUR2B_S1351) with either non-polar alanine or polar asparagine causes 
disruption of the channel activation by PKA stimulation. Therefore, Ser1351 is an 
important site for channel regulation although it does not seem to be phosphorylated by 
PKA.  
Why is it that mutation of the corresponding residue in NBD1 (Ser710) does not 
affect channel activation by PKA? This may be related to the difference in the function of 
NBD1 and NBD2. The NBD1 in SURx hosts a Mg2+-independent high-affinity nucleotide-
binding domain while the nucleotide-binding domain in NBD2 is Mg2+-dependent and 
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low-affinity (Matsuo et al., 2005). Thus mutation of the serine residue in NBD1 may have 
little effect on nucleotide binding and channel activity.  
10.4.4. The Ser1387 is an important PKA site: its functional implication in SUR1 
and SUR2A channels.  
Ser1387 is a phosphorylation site critical for the channel regulation by PKA, as 
shown in our pharmacological studies, mutagenesis analysis, in vitro phosphorylation 
assay and direct exposure to cPKA. This is a novel finding in comparison to previous 
studies in PKA regulation on KATP channels. Lin et al. (Lin et al., 2000) and Beguin et al. 
(Beguin et al., 1999) have found that PKA activates Kir6.2/SUR1 through 
phosphorylation of the Kri6.2 subunit (Ser224 and Ser372, respectively). The SUR1 
subunit has also been proposed as a target of PKA. Beguin et al. (Beguin et al., 1999) 
reported that a human specific residue on SUR1 (Ser1571) has basal level 
phosphorylation. Light et al. (Light et al., 2002) reported that the Kir6.2/SUR1 channel is 
inhibited by the glucagon-like peptide through PKA phosphorylation at Ser1448 of the 
SUR1 subunit. Both PKA sites on SUR1 subunit are located in the NBD2 in which ADP 
binding takes place (Matsuo et al., 2005). Thus, it is possible that PKA phosphorylation 
affects ADP sensitivity and thus the channel activity (Light et al., 2002). These two sites 
are SUR1-specific, as the corresponding sites are not phosphorylatable residues or not in 
a consensus PKA sequence in SUR2B. In contrast, our newly identified PKA 
phosphorylation site Ser1387 in SUR2B is conserved among species and in all three 
SURx (Fig. 10-9A). It is of interest to know whether such a site plays a role in other 
isoforms of KATP channels.  
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Figure 10-9. The sites important for PKA regulation on KATP channels.  
A. Alignment of NBD2 of mouse SUR2A, SUR2B (residue 1339-end) and human SUR1 
(residue 1376-end). The Nucleotide binding Walker A (WA) and Walker B (WB) are underlined. 
The S1351 that is important for PKA activation, the PKA phosphorylation site (S1387) in SUR2B 
and the conserved sites in SUR2A and SUR1 are highlighted in reverse form. The previously 
suggested PKA site (S1465) in SUR2B and sites (S1448 and S1571) in SUR1 are also 
highlighted. B. Schematic representation of Kir6.1 and SUR2B. The nucleotide binding domain 1 
(NBD1) and 2 (NBD2) and Walker A (WA) and Walker B (WB) and N, C terminus are illustrated. 
The relative positions of important sites (Kir6.1_Thr234, Ser385 and SUR2B_Thr633, Ser1351, 
Ser1387, Ser1465) are marked. Note the Kir6.1_Thr234 and Ser385 are also the corresponding 
sites of Kir6.2_Thr224 and Ser372. 
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Figure 10-9 
                    1351                                1387 
mSUR2B   GICGRTGSGKSSLSLAFFRMVDIFDGKIVIDGIDISKLPLHTLRSRLSIILQDPILFSGS  
mSUR2A   GICGRTGSGKSSLSLAFFRMVDIFDGKIVIDGIDISKLPLHTLRSRLSIILQDPILFSGS  
hSUR1    GICGRTGSGKSSFSLAFFRMVDTFEGHIIIDGIDIRKLPLHTLPSRLSIILQDPVLFSGT  
                WA  1387                                1423        
 
mSUR2B   IRFNLDPECKCTDDRLWEALEIAQLKNMVKSLPGGLDATVTEGGENFSVGQRQLFCLARA  
mSUR2A   IRFNLDPECKCTDDRLWEALEIAQLKNMVKSLPGGLDATVTEGGENFSVGQRQLFCLARA  
hSUR1    IRFNLDPERKCSDSTLWEALEIAQLKLVVKALPGGLDAIITEGGENFSQGQRQLFCLARA  
                    1448 
              1465                             
mSUR2B   FVRKSSILIMDEATASIDMATENILQKVVMTAFADRTVVTIAHRVHTILTADLVIVMKRG  
mSUR2A   FVRKSSILIMDEATASIDMATENILQKVVMTAFADRTVVTIAHRVSSIVDAGLVLVFSEG  
hSUR1    FVRKTSIFIMDEATASIDMATENILQKVVMTAFADRTVVTIAHRVHTILSADLVIVLKRG  
                 WB                 
 
mSUR2B   NILEYDTPESLLAQEDGVFASFVRADM 1546 
mSUR2A   ILVECDTGPNLLQHKNGLFSTLVMTNK 1546 
hSUR1    AILEFDKPEKLLSRKDSVFASFVRADK 1581 
                         1571        
A 
C
S1465 
WB 
WA 
WA
WB 
S1351 
T633 
S1387 
N C 
T234 S385 
NB Kir6.1 SUR2B
NBD1 NBD2 
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It should be noted that S1387 cannot explain the full effects of PKA, as cPKA can 
moderately activate the Kir6.1/SUR2B_S1387A channel in the inside-out configuration 
(Fig. 6B). This may be due to the presence of other unconventional PKA sites that were 
not detected by our PKA consensus sequence screening. Besides, the possibility of 
phosphorylation on Ser1351 cannot be excluded as the isolated peptide may differ in 
protein folding, losing the capability to be phosphorylated. In addition, there may be 
other adaptor proteins and scaffolds absent in the in vitro phosphorylation assay, such as 
A-kinase anchoring proteins (Hayabuchi et al., 2001a) and coveolae (Sampson et al., 
2004) that are important for PKA modulation of native vascular KATP channels.  
In conclusion, our results indicate that the Kir6.1/SUR2B channel can be a down-
stream effecter of β2 receptors. In this case, channel activation involves Gs, adenylyl 
cyclase, cAMP and PKA. Two serine residues (Ser1351 and Ser1387) in the SUR2B 
subunit are important for PKA activation and the channel protein is likely phosphorylated 
at Ser1387. The demonstration of an effecter protein of β2-ARs and intracellular signaling 
cascades may allow for the creation of therapeutical modalities. By targeting these 
molecules and their regulators, it may be possible to control vascular tone more 
effectively.  
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11. Result 2: PKA Phosphorylation Produces Interdomain Movement in 
SUR2B Suggesting a Gating mechanism for Activation of the Vascular 
KATP Channel 
 
 
 
 
 
 
Manuscript submitted: Shi Y, Chen X, Wu Z, Shi W, Jiang C, Harrison R. (2007) PKA 
Phosphorylation produces interdomain movements in SUR2B leading to activation of 
vascular KATP channel.  
 
Note: Yun Shi did ~80% of molecular construction and patch clamp experiments. Mr. 
Xianfeng Chen did molecular modeling. Ms. Zhongying Wu and Mr. Weiwei Shi helped 
in patch experiments. Generally, Shi Y and Chen X contribute to ~40% of the work. 
Therefore, Yun Shi and Xianfeng Chen are considered equal contributors to this work.  
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11.1. Abstract 
Vascular KATP channels are activated by multiple vasodilating hormones and 
neurotransmitters via a cAMP-PKA signaling pathway. A critical PKA phosphorylation 
site (Ser1387) in NBD2 of SUR2B subunit was revealed in our recent study. To 
understand how phosphorylation at Ser1387 leads to changes in channel activity, we used 
a newly crystallized ABC protein, SAV1866, to model the SUR2B core containing both 
nucleotide-binding domains (NBD1, NBD2) as well as two transmembrane domains 
(TMD1, TMD2). On the model, Ser1387 was located on the interface between TMD1 and 
NBD2 and physically interacted with an aromatic residue (Tyr506) in TMD1. A positively 
charged residue (Arg1462) in NBD2 was also in the vicinity of Ser1387. Mutations of 
Arg1462 or Tyr506 abolished the PKA-dependent channel activation. Molecular 
dynamics simulations suggested Ser1387, Tyr506 and Arg1462 formed a compact triad 
upon phosphorylation at Ser1387. The simulations also suggested that the 
phosphorylation reshaped the NBD2 interface and caused movement of TMD1 
(represented by a short intracellular linker segment, ICL2), strengthening the interaction 
between these two protein domains. Restriction of the hypothetical interdomain 
movement by introducing a disulfide bond between them prevented channel activation. 
The combination of modeling, molecular dynamics, and experimental protein engineering 
suggests a mechanism for the transfer of information of protein phosphorylation to 
channel activation. 
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11.2. Introduction 
KATP channels play a crucial role in vascular tone regulation (Quayle et al., 1997; 
Rosenblum, 2003; Seino & Miki, 2003; Jackson, 2005). The channels are expressed in 
VSMs and activated by several vasodilating hormones most likely through a Gs-cAMP-
PKA signaling system (Quayle et al., 1997; Shi et al., 2007b; Quinn et al, 2004). Critical 
phosphorylation sites have been found in the SUR2B subunit (Shi et al., 2007b). Channel 
activation leads to hyperpolarization of VSM cells, a decrease in voltage-dependent Ca2+ 
channel activity and relaxation of resistant arteries (Nelson et al., 1995).  
KATP channels consist of 4 pore-forming Kir6 and 4 regulatory SUR subunits 
(Nichols, 2006). Kir6.1/SUR2B is the major isoform of KATP channels in VSMs (Yamada 
et al., 1997; Cui et al., 2002; Cole & Clement-Chomienne, 2003; Li et al., 2003). The 
channel does not open spontaneously at rest. Several groups of channel openers activate 
the channel, including pharmacological KATP channel openers (KCOs, pinacidil, 
nicorandil) (Yamada & Kurachi, 2004; Moreau et al., 2005), metabolites (MgADP, 
acidosis) (Matsushita et al., 2002; Wang et al., 2003), and hormonal vasodilators 
(calcitonin gene-related peptide, epoxyeicosatrienoic acids, beta-adrenergic receptor 
agonists and vasoactive intestinal peptide) (Wellman et al., 1998; Lu et al., 2001; Shi et 
al., 2007b; Yang et al., 2007). KCOs and Mg2+-nucleotides activate the Kir6.1/SUR2B 
channel via binding to the SUR subunit (Yamada & Kurachi, 2004; Moreau et al., 2005; 
Nichols, 2006). Hormonal vasodilators activate the vascular KATP channel through direct 
phosphorylation of the channel protein by PKA (Quinn et al., 2004; Shi et al., 2007b). 
 
 
73
Our resent study has shown that Ser1387 in SUR2B is a key phosphorylation site (Shi et 
al., 2007b).  
It is unclear how phosphorylation at Ser1387 in SUR2B leads to channel 
activation. SURx belong to the family of ABC transporter proteins (Higgins, 1992; 
Moreau et al., 2005). All ABC proteins have similar domain assemblies, i.e. two 
transmembrane domains (TMD1 and TMD2) and two intracellular nucleotide-binding 
domains (NBD1 and NBD2). In SURx, an additional transmembrane domain containing 5 
helical segments termed TMD0 is linked to TMD1 with intracellular liker-0 (ICL0, Fig. 
11-1A). The NBDs of several ABC proteins have been crystallized (Gaudet & Wiley, 
2001; Smith et al., 2002; Verdon et al., 2003). They all show similar sandwich-like 
structures with nucleotides clamped between the signature sequence of one NBD and the 
Walker-A motif of the other NBD. The Walker-A (Gribble et al., 1997; Yamada & 
Kurachi, 2004), Walker-B (Shyng et al., 1997; Huopio et al., 2000; Yamada et al., 2004), 
and signature sequences (Matsuo et al., 2002) are known to be important in nucleotide 
and/or KCO activation of KATP channels, although how nucleotide/KCO-binding couples 
to channel activity is still not fully understood. Several lines of evidence suggest that 
SUR TMDs play a major role in interacting with Kir6 subunits (Schwappach et al., 
2000). Such interaction has been observed in the recombinant Kir6.2/SUR1 channel 
using electron microscopy (Mikhailov et al., 2005). In addition, the TMD0 and ICL0 are 
involved in KATP gating by channel modulators and nucleotides (Babenko & Bryan, 
2003; Chan et al., 2003). These data suggest that NBDs couple with TMDs during SUR-
mediated channel gating.  
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Several ABC proteins have been recently crystallized (Locher et al., 2002; 
Dawson & Locher, 2006; Hollenstein et al., 2007; Pinkett et al., 2007). Of them, 
SAV1866 (Dawson & Locher, 2006) shows highest homology to SUR2B. Using the 
SAV1866 crystal structure, we modeled SUR2B core paying particular attention to 
protein conformational changes following Ser1387 phosphorylation. Our combined 
studies with functional assays, mutagenesis analysis and molecular dynamics simulation 
suggest that conformational changes in two protein domains, NBD2 and intracellular 
linker-2 (ICL2), underscore PKA-dependent channel activation.  
 
Figure 11-1. Alignment of SUR2B and SAV1866.  
TM-NBD1 and TM-NBD2 refer to residues 286-914 and 976-1546 of SUR2B. Residues 
in SUR2B identical and similar to SAV1866 were shaded in cyan and green respectively. Six 
transmembrane helices (TMH1-6) in SAV1866 are shown in bold and underlined, which 
correspond to TMH6-11and TMH12-17 in SUR2B_TMD1 and TMD2 respectively. Sequences 
between SAV1866 TMH2 and 3, and between SAV1866 TMH4 and 5 are intracellular linkers. 
Short helices that are critical for TMD-NBD interactions are shown in red. ICL1, ICL2 are located 
in SAV1866 and SUR2B_TMD1 while ICL3, ICL4 in SUR2B_TMD2. Although the homology in 
TMDs between SAV1866 and SUR2B is low, the lengths of TMHs are the same. The lengths of 
intracellular and extracellular linkers are comparable. Therefore, when they are aligned, there are 
only 4 short gaps in TMD1, and 2 gaps in TMD2. The similar topology allowed us to model 
SUR2B TMDs with SAV1866 template. The homology in NBDs is higher. Critical motives such 
as Walker A (WA), Walker B (WB), Signature Sequence (SS), Q-loop and H-loop in NBDs are 
conserved (in red). The secondary structures in SAV1866_NBD were shown in bold and 
underlined. The loop between α3 and α4 helices was named C-loop as Cys1408 was found in it. 
Tyr506, Ser1387 and Arg1462 in SUR2B are shown in bold and italic, and are critical for PKA 
activation.  
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Figure 11-1 
                     TMH1                                               TMH2  
SAV1866   MIKRYLQFVKPYKYRIFATIIVGIIKFGIPMLIPLLIKYAIDGVINN----HALTTDEKVHHLTIAI  
TM-NBD1   WLAMYRAFGRPILLSSTFRYLADLLGFAGPLCISGIVQRVNEKTNTTREMFPETLSSKEFLENAHVL  
TM-NBD2   WKTCWWYLTSGGFFLLFLMIFSKLLKHSVIVAIDYWLATWTSEYSIN----HPGKADQTFYVAGFSI  
   
                                                         ICL1/3 
SAV1866   GIALFIFVIVRPPIEFIRQYLAQWTSNKILYDIRKKLYNHLQAL—-SARFYANNQVGQVISRVINDV  
TM-NBD1   AVLLFLALILQRTFLQASYYVTIETGINLRGALLAMIYNKILRLSTSNLSMGEMTLGQINNLVAIET  
TM-NBD2   LCGAGIFLCLVTSLTVEWMGLTAAKNLH------HNLLNKIILG--PIRFFDTTPLGLILNRFSADT  
 
               TMH3                         TMH4   
SAV1866   EQTKDFILTGLMNIWLDCITIIIALSIMFFLDVKLTLAALFIFPFYILTVYVFFGRLRKLTRERSQA  
TM-NBD1   NQ-LMWFLFLCPNLWAMPVQIIMGVILLYNLLGSSALVGAAVIVLLAPIQYFIATKLAEAQKSTLDY  
TM-NBD2   NIIDQHIPPTLESLTRSTLLCLSAIGMISYATPVFLVALAPLGVAFYFIQKYFRVASKDLQELDDST  
 
                        ICL2/4                           TMH5 
SAV1866   LAEVQGFLHERVQGISVVKSFAIEDNEAKNFDKKNTNFLTRALKHTRWNAYSFAAINTVTDIGPIIV  
TM-NBD1   STERLKKTNEILKGIKLLKLYAWEHIFCKSVEETRMKELSSL-KTFALYTSLSIFMNAAIPIAAVLA  
TM-NBD2   QLPLLCHFSETAEGLTTIRAFRHETR----FKQRMLELTDTNNIAYLFLSAANRWLEVRTDYLGACI  
                             Y506 
                           TMH6           
SAV1866   IGVGAYLAISGSITVGTLAAFVGYLELLFGPLRRLVASFTTLTQSFASMDRVFQLIDED--------  
TM-NBD1   TFVTHAYASGNNLKPAEAFASLSLFHILVTPLFLLSTVVRFAVKAIISVQKLNEFLLSDEIGEDSWR  
TM-NBD2   VLTASIASISGSSNSGLVGLGLLYALTITNYLNWVVRNLADLEVQMGAVKKVNSFLTME--------  
 
                                                            β1    
SAV1866   ----------YDIKNGVGAQPIEIKQ----------------------GRIDIDHVSFQYNDNEAPI  
TM-NBD1   AGEGTLPFESCKKHTGVQSKPINRKQPGRYHLDSYEQARRLRPAETEDIAIKVTNGYFSWGSGLAT-  
TM-NBD2   -------SENYEGTMDPSQVPEHWPQE---------------------GEIKIHDLCVRYENNLKPV  
 
          β2          β3      WA α1             β4             α2         β5 
SAV1866   LKDINLSIEKGETVAFVGMSGGGKSTLINLIPRFYDVTSGQILIDGHNIKDFLTGSLRNQ----IGL  
TM-NBD1   LSNIDIRIPTGQLTMIVGQVGCGKSSLLLAILGEMQTLEGKVYWNNVNESEPSFEATRSRSRYSVAY  
TM-NBD2   LKHVKAYIKPGQKVGICGRTGSGKSSLSLAFFRMVDIFDGKIVIDGIDISKLPLHTLRSR----LSI  
                                                                         S1387 
            Q-loop   α3    C-loop α4           α5                   SS α6 
SAV1866   VQQDNILFSDTVKENILLGRPTATDEEVVEAAKMANAHDFIMNLPQGYDTEVGERGVKLSGGQKQRL  
TM-NBD1   AAQKPWLLNATVEENITFGSPFN-RQRYKAVTDACSLQPDIDLLPFGDQTEIGERGINLSGGQRQRI  
TM-NBD2   ILQDPILFSGSIRFNLDP-ECKCTDDRLWEALEIAQLKNMVKSLPGGLDATVTEGGENFSVGQRQLF  
 
                     β6 WB        α7                  β7    H-loop    β8 
SAV1866   SIARIFLNNPPILILDEATSALD-LESESIIQEALDVLSKD--RTTLIVAHRLSTITHADKIVVIEN  
TM-NBD1   CVARALYQNTNIVFLDDPFSALDIHLSDHLMQEGILKFLQDDKRTVVLVTHKLQYLTHADWIIAMKD  
TM-NBD2   CLARAFVRKSSILIMDEATASID-MATENILQKVVMTAFAD--RTVVTIAHRVHTILTADLVIVMKR  
                R1462 
           β9     α8        α9 
SAV1866   GHIVETGTHRELIAKQG-AYEHLYSIQNL  
TM-NBD1   GSVLREGTLKDIQTKDVELYEHWKTLMNR  
TM-NBD2   GNILEYDTPESLLAQED-GVFASFVRADM 
TMDs 
NBDs 
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11.3. Results 
11.3.1. Alignment of SUR2B with SAV1866 
The sequences of SAV1866 were aligned with both halves of SUR2B core (TM-
NBD1 and TM-NBD2) using ClustalW (Thompson et al., 1994). SAV1866 was 21.5% 
identical to TM-NBD1 of SUR2B (46.5% similarity) and 21.3% to TM-NBD2 (47.8% 
similarity). The NBDs were highly conserved, with 28.7% identity in NBD1 and 33.5% in 
NBD2. The SAV1866 TMD was 16.0% and 12.8% identical to SUR2B_TMD1 and 
TMD2 respectively (~35% when amino acids with similar side chain were considered). 
Although the homology in primary sequences in TMDs is low, we were still able to align 
them because their topology within each TMD was the same, i.e., 6 transmembrane 
helices (determined by hydrophobicity plots) in each domain with similar lengths. The 
sizes and position of extracellular and intracellular linker regions were also comparable. 
There were only a few short gaps in alignment (4 in TMD1 and 2 in TMD2, Fig. 11-1). 
The similarity in the topology suggests the two proteins have the same structural 
arrangements, allowing modeling of SUR2B using SAV1866 structure.  
11.3.2. Modeling of the SUR2B_core  
The dimerized SAV1866 was crystallized in ADP binding form (PDB: 2hyd). 
Based on this structure, we built a SUR2B core model (Fig. 11-2B), in which NBD1 and 
NBD2 formed a tight hetero-dimer (Fig. 11-2C). On the interface between NBD1 and 
NBD2 there were two nucleotide-binding pockets. A MgATP molecule was incorporated 
in the first nucleotide binding pocket and a MgADP in the second pocket. Different 
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nucleotides were used because the first pocket is likely to be a high-affinity ATP-binding 
site, and second to bind to MgADP (Bienengraeber et al., 2000; Matsuo et al., 2005). In 
the SUR2B_core model, the TMDs interact with the NBDs via four short helices of the 
intracellular linkers (ICLs, Fig. 11-2C). ICL1 and ICL3 interacted with the NBD surface 
across the nucleotide-binding regions. ICL2 from TMD1 inserted deeply into NBD2, while 
ICL4 from TMD2 inserted into NBD1 (Fig. 11-2C). The NBD2 formed a spindle-like 
groove where a β sheet (β5) formed the bottom while the Q-loop, C-loop and several α-
helices (α2, α3 and α6) lined the wall. Ser1387 was located on β5 within the reach of 
ICL2 (Fig. 11-2D). The side-chain of an aromatic residue (Tyr506) in ICL2 was inserted 
deeply into the NBD2 groove roughly ~4Ǻ from Ser1387 (Fig. 11-3A). Around the 
Ser1387 there was a positively charged residue (Arg1462) in NBD2, ~8Ǻ from Ser1387 
(Fig. 11-3A).  
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Figure 11-2. SUR2B core Model.  
A. A skeletal representation of KATP channel. SUR2B has 17 TMHs, forming three 
transmembrane domains (TMD0, TMD1 and TMD2). The nucleotide binding domain-1 (NBD1) is 
located between TMD1 and TMD2, and NBD2 is located C-terminal to TMD2. The intracellular 
linkers (ICLs) between TMHs are indicated. SUR2B core is defined as TMD1 to C-terminus. The 
region between residue 286 (arrow-1, a1) and 914 (a2) was taken as TM-NBD1. The sequence 
between 976 (a3) and 1546 (C-terminus) was taken as TM-NBD2. TM-NBD1 and TM-NBD2 
were aligned to SAV1866 and used to generate the SUR2B core model. The sequence between 
a2 to a3 was omitted in SUR2B core model as it is not homologous to SAV1866. B. The 
overall structure of SUR2B core. TMD1 (residues 286-617, green) was linked with NBD1 
(residues 666-913, blue) with 38 residues (loop in gray). TMD2 (residues 976-1289, red) was 
linked with NBD2 (residues 1310-1546, purple) with 20 residues. The linker regions between 
TMD1 and NBD1, TMD2 and NBD2 were looped beside the NBD domains (gray). The first 
nucleotide binding pocket (formed by Walker A in the NBD1 and signature sequence in the 
NBD2) was modeled with ATP (yellow). The second nucleotide binding pocket was modeled 
with ADP. C. Interaction of the intracellular linkers and NBDs. The ICL1 and ICL3 interacted 
with both NBD1 and NBD2 across the nucleotide-binding regions (yellow). ICL2 inserted into a 
groove that is formed by the NBD2 surface, and ICL4 interacted with NBD1. D. Details of the 
interaction between ICL2 and NBD2. The NBD2 formed a big groove for binding of ICL2. β5 of 
NBD2 formed the bottom of the groove. Q-loop, α2, α3, α6, and C-loop between α3 and α4 
formed the wall of the groove. The phosphorylation site Ser1387 was located in the β5 sheet and 
is shown in cyan. Critical residues like Tyr506 and Arg1462 are also shown.  
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Figure 11-2 
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Figure 11-3. Forskolin effects on wt and mutant Kir6.1/SUR2B.  
A. Ser1387 was close to Tyr506 and Arg1462. The atom Og in Ser1387 side-chain was 
3.6Å to atom Oh of Tyr506 and ~8Å to the positive charge of ArgR1462 (the middle of the two Nh 
atoms). B. Forskolin activated whole cell currents of Kir6.1/SUR2B, which were further activated 
by pinacidil and inhibited by glibenclamide. C. The channel with SUR2B_R1462A mutant failed 
to be activated by forskolin. D. SUR2B_Y506A mutant diminished forskolin activation of the 
channel. E. Summary of forskolin effects on wt and mutant Kir6.1/SUR2B channels. Note the 
Y506F mutant was not activated and the R1462K mutant was activated by forskolin.  
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11.3.3. Activation of the Kir6.1/SUR2B channel by forskolin  
β-Adrenergic receptor agonists activate vascular KATP channels in rat mesenteric 
artery, a response that can be reproduced in recombinant Kir6.1/SUR2B channel 
expressed in HEK293 cells. Forskolin (10µM) activates Kir6.1/SUR2B currents to 
38.5±3.0% of maximal activation by pinacidil in HEK cells (n=10, Fig. 11-3E). We 
therefore chose to study forskolin activation of recombinant Kir6.1/SUR2B expressed in 
HEK cells. We focused on the interaction of ICL2 and NBD2 as this is where PKA exerts 
its effects.  
11.3.4. Elimination of PKA activation by mutation at Arg1462 or Tyr506 
In our SUR2B_core model, a positively charged residue Arg1462 was located in 
the vicinity of Ser1387. The distance of the charge of Arg1462 (measured at the center of 
two Nh atoms) to Ser1387 side chain (Og) was ~8Ǻ (Fig. 11-3A). This small distance 
might allow an electronic attraction between the two amino acids when Ser1387 was 
phosphorylated. Mutation of Arg1462 to alanine indeed eliminated the forskolin-induced 
channel activation (Fig. 11-3C). Based on our model, positive charge at this site appears 
important. This prediction was verified by mutating the Arg1462 to lysine, and the 
R1462K mutant remained strongly activated by forskolin (68.5±5.8%, n=5). The 
Arg1462 is located in a consensus PKA site (RKSS), although neither Ser1464 nor 
Ser1465 is a functional PKA phosphorylation site (Shi et al., 2007b). Thus, a positively 
charged residue critical for the PKA-dependent channel activation is identified in the 
SUR2B_core model, although it is far from Ser1387 in the primary sequence. 
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An aromatic residue, Tyr506 was in ICL2, deeply inserted its side chain into 
NBD2 and physically interacted with Ser1387. When Tyr506 was mutated to alanine, the 
forskolin-induced channel activation was significantly diminished (Fig. 11-3D). A 
phenylalanine residue is found at the corresponding site in SAV1866 and SUR2B_ICL4 
(Fig. 11-1). The side chain of phenylalanine is similar to tyrosine but lacks a hydroxyl 
group. Interestingly, when Tyr506 was mutated to phenylalanine, the channel failed to be 
activated by forskolin (Fig. 11-3E). These data indicate that channel activation involves 
Tyr506. 
11.3.5. Triad formation by Arg1462, Tyr506 and Ser1387 following PKA 
phosphorylation 
Our mutational analysis suggests that PKA phosphorylation at Ser1387 induces 
conformational changes in the local area. In order to understand these changes, we used 
molecular dynamics simulations to reveal changes the peptide backbone. Our SUR2B 
core contained a large number of hydrophobic transmembrane segments that are 
technically difficult to run in molecular dynamics simulations. We therefore constructed 
two additional models consisting of NBDs and ICL2 helix with and without 
phosphorylation at Ser1387. MD simulations were run at 310K and 1 atm. After 1000 
runs, the ICL2 still stayed in the groove formed by NBD2, suggesting the interaction 
between ICL2 and NBD2 is strong. The distances between the side chains of the three 
critical residues were monitored (Fig. 11-4A, B). Without phosphorylation, the average 
distance between Tyr506 and Ser1387 was 3.8Ǻ, a distance that allows hydrogen bond 
formation between these two residues. The Tyr506-Arg1462 and Ser1387-Arg1462 
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distances were around 6-7Ǻ (Fig. 11-4A, C), suggesting that there is no direct contact 
between Arg1462 and the other two residues before Ser1387 phosphorylation. When the 
Ser387 was phosphorylated, all the three distances were reduced to less than 4Ǻ (Fig. 11-
4C), indicating a stable triad formed following phosphorylation (Fig. 11-4D, E). The 
hydroxyl group of Tyr506 appeared to be critical for stabilization of the triad, which 
could form hydrogen bonds with oxygen atoms of the phosphate group of p-Ser1387 and 
Nh atoms in Arg1462, consistent with our observation that forskolin failed to activate the 
Y506F mutant (Fig. 11-3E).  
 
Figure 11-4. Formation of a compact triad among Tyr506, Ser1387 and Arg1462 following 
phosphorylation.  
Molecular dynamic simulations were run on the ICL2 with a short flanking 
sequence (residues 500 to 512) and NBDs. A phosphate group was linked to atom Og in 
Ser1387 representing post-phosphorylation. A. The distances between each two of the three 
residues were monitored in pre-phosphorylation form. Y-S was measured between Tyr506-Oh 
and Ser1387-Og. Y-R was measured between Tyr506-Oh and Arg1462-Nh1 or Nh2 
depending on which one atom was closer to Tyr-Oh. And so was S-R. B. The distances in 
post-phosphorylation form. pS represented one of the three Op atoms in phosphorylated 
Ser1387. Six distances were measured between p-Ser1387 and Arg1462, and three 
between Tyr506 and p-Ser1387, while only the closest distances were shown in the 
figure. C. The summary of the distances among the three residues pre- and post-
phosphorylation. Since the molecules in the initial ~200 time frames might be unstable 
(see A and B), only the last 800 time frames were counted. All three distances were shorter in the 
post-phosphorylated form (P<0.001 for every distance). Y-S shortened from 3.80±0.02Å to 
3.13±0.02Å. Y-R shortened from 6.62±0.03Å to 3.61±0.01Å. S-R shortened from 6.43±0.02Å to 
2.88±0.00Å. Major changes were seen in distances between Ser1387 and Arg1462, and Tyr506 
and Arg1462, suggesting the Arg1462 side chain moves toward Ser1387 and Tyr506 and forms a 
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stable triad. D. The mode structure of the post-phosphorylation form showing the triad. E. 
Enlargement of the boxed region in D. The numbers in the figure are the distances (in Ǻ) between 
the interested residues. They are slightly, but not significantly, different from the average 
distances shown in C.  
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11.3.6. The movement of ICL2 
Following phosphorylation, the Tyr506 Cα atoms (α carbon) moved by 9.2Ǻ in 
the mode structures (see methods). The movement led to a horizontal shift of ICL2 from a 
position close to the center of NBD2 toward the edge of NBD2 along the NBD2 groove. 
Since the MD data were acquired after removing most TMDs, the restriction of ICL2 by 
TMDs was not evaluated. Therefore, this ~10Ǻ movement might be overestimated. 
However, the direction appeared reasonable. The Arg1462 was located at the end of α6 
helix, close to the edge of NBD2, while Ser1387 was located on the bottom of the NBD2 
groove. With the triad formation, ICL2 was pulled toward NBD2 with lateral sliding along 
the groove. Meanwhile, the α2 helix in NBD2 made a lateral move and left space for ICL2 
(Fig. 11-5).  
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Figure 11-5. The movement of ICL2 
following phosphorylation. 
 All pictures represent the mode 
structures in MD study. A.B.C. The 
top views of ICL2 and NBD2 in pre-
phosphorylation, post-phosphorylation 
and overlay respectively. The NBD2 
was shown in purple and red in pre 
and post-phosphorylation forms. The 
ICL2 was shown in green and cyan in 
pre and post phosphorylation forms. 
The NBD1 and nucleotides were 
shown in blue and yellow 
respectively. Compared to the mode 
structure of pre-phosphorylated form, 
the ICL2 helix moves horizontally 
from the center of NBDs toward 
NBD2 edge with 8.4±0.4Ǻ (measured 
at Cαs of residues 500-506). 
Accordingly, the α2 helix in NBD2 
moved to yield space for ICL2. The 
arrows in C. indicate the direction of 
movement of ICL2 and α2 helices. 
 
 
 
 
ICL2 
α2 
C 
ICL2 
α2 
α6 
α3 
B 
ICL2 
β5 
α2 
α6 
α3 
A 
 
 
87
 
11.3.7. The NBD2 groove is reshaped by phosphorylation  
Studying the conformations of NBD2 of pre- vs. post-phosphorylation, we found 
that the NBD2 domain underwent major conformational changes at the interface with the 
ICL2. The groove for binding the ICL2 consisted of residues from β5, α2, α3, α6, Q-loop 
and C-loop. The Arg1462 was the last residue of the long α6 helix, located close to the 
edge of NBD2. The α6 helix was expected to be stable because it was buried in the 
structure. Indeed, Cαs in the corresponding segment in NBD1 did not significantly change 
their positions (1.8±0.2Ǻ, Fig. 11-6D) in comparison to overall movements of Cαs in 
NBDs (3.4±0.1Ǻ). However, the phospho-Ser1387 (p-Ser1387) attracted the positively 
charged Arg1462, moving the residue by 4.5Ǻ toward ICL2 (measured at Cα, Fig. 11-6C). 
This movement had major effects on the C-terminal half (tail) of α6 (residues 1455-1462) 
but not the N-terminal half (head) (residues 1448-1454). The average movement of Cαs in 
the tail was 4.2±0.3Ǻ, much greater than the head (2.2±0.3Ǻ). Consequently, the α6 helix 
was slightly bent around Phe1454 and turned toward the ICL2 with an angle ~10o. The 
movement of the α6 helix appeared to cause the α3 helix to move toward ICL2 about 
4.2±0.7Ǻ. Like the head of α6 helix, the Q-loop was quite stable (2.4±0.3Ǻ). The Cαs in 
β5 sheet moved toward the ICL2 with distance of 3.0±0.4Ǻ. The β5 movement was 
greater than the overall movements of β-sheets in the NBD2 (2.3±0.2Ǻ, P=0.11) and the 
corresponding segment in the NBD1 (2.4±0.2Ǻ, P=0.07). The movement of these 
segments toward ICL2 suggested a stronger interaction between the ICL2 and the NBD2 
following phosphorylation. We also observed a large movement (6.9±0.3Ǻ) of the α2 
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helix. The α2 helix appeared flexible in the SUR2B_core model; it moved toward the 
edge of NBD2 and yielded space for the ICL2. 
 
Figure 11-6. The conformational changes in NBD2 interface.  
A.B.C The side views of NBD2 interface in pre-phosphorylation, post-phosphorylation 
and overlay respectively. The backbone of the Arg1462 moved 4.46Å toward ICL2, which caused 
a movement of the α6-tail (residue 1455-1462). Major changes in position were also seen with α2 
and α3 helices. The arrows in C. indicate the direction of movement of α6, α3 and α2. D. 
Analysis of critical residue and segments. Major changes were seen on NBD2-α6-tail, α3 and α2, 
compared to the corresponding segments in NBD1 (*, P<0.05; **, P<0.01). The α6 helix was long 
(15 residues) and buried in the NBDs, which were expected to be stable. Indeed, the α6 helix in 
NBD1 was very stable and moved less than the overall structure. The formation of the triad 
changed Arg1462 and moved the α6-tail 4.2±0.3Å toward ICL2. The α3 and its flanking sequence 
in C-loop were moved following the change in the α6-tail. The triad might also affect β5, which 
appeared to change more than overall β sheets (2.3±0.2Ǻ, P=0.11) in NBD2 and the 
corresponding segment in NBD1 (2.3±0.2Ǻ, P=0.07). The α2 helices in both NBDs changed large 
distance suggesting they are flexible, while the α2 helix in the NBD2 moved more to the edge of 
NBDs, giving space for ICL2 (also see Fig. 11-5). On the other hand, the NBD2-α6-head and the 
Q-loop did not significantly change position.  
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To make sure that these movements were not random events, the MD simulations 
were repeated twice for a total of three times with different starting velocities. We 
observed the same triad formation and protein domain movements in every runs. 
Therefore, even though there may be technical limitations in the MD simulations, we 
were able to conclude that the ICL2 interacted with the NBD2 rather loosely before 
phosphorylation, and the interaction of the two domains was strengthened with the 
Tyr506-pSer1387-Arg1462 triad formation after phosphorylation. 
11.3.8. Restriction of the interdomain movement by disulfide bond  
Mutations were engineered in the channel to test the hypothesis that interdomain 
motion plays a critical role in PKA-dependent channel activation. Forming a disulfide 
bond between the two domains can restrict the motion thus limiting the channel 
activation if the motion is critical for channel activation. Examining all residues in the 
NBD2 groove and the ICL2, we found that a cysteine (Cys1408) on the wall of the NBD2 
groove was close to Ala507 in the ICL2 (Fig. 11-7A). The distance between the Cαs of the 
two residues was ~8Å. When the Ala507 was mutated to cysteine, the channel activation 
by forskolin was completely eliminated (Fig. 11-7B). Since the Ala507 is located next to 
Tyr506, the mutation itself instead of the disulfide bond formation could have affected 
the channel activation. To address this possibility, we included 3mM reduced glutathione 
in the pipette solution and found that the Kir6.1/SUR2B_A507C channel activation by 
forskolin was nicely restored (29.7±3.0%, N=5, P>0.05 compared to wt, Fig. 11-7C). To 
show whether the introduced Cys507 indeed formed a disulfide bond with Cys1408 but 
not with another unidentified cysteine residue, we mutated the Cys1408 to serine, a 
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residue close to cysteine in side chain properties, but which is unable to form disulfide 
bonds. The mutant channel (Kir6.1/SUR2B_A507C_C1408S) was activated by forskolin 
to the same extend as wild type channel (Fig. 11-7D, E). Thus, the formation of an 
artificial disulfide bond between residues 507 and 1408 locked the channel in the pre-
phosphorylation state and disrupted the channel activation by forskolin, supporting the 
hypothesis that a relative movement between the ICL2 and NBD2 is necessary for channel 
activation by PKA. We also tried to use disulfide bond to lock the channel in its open 
state without success.  
11.4. Discussion 
11.4.1. The rational to choose SAV1866 to model SUR2B_core.  
The KATP channel regulatory subunit SURx (abcc8 and abcc9) belongs to the 
ABC transporter superfamily. Four ABC proteins have been recently crystallized in full 
length with TMDs and NBDs. The NBDs are similar to each other in their overall 
structures and assemblies. The TMDs however, are much different. There are 10 TMHs 
in each TMD in HI1470/1 (Pinkett et al., 2007) and BtuCD (Locher et al., 2002) while 6 
each in SAV1866 (Dawson & Locher, 2006) and ModBC (Hollenstein et al., 2007). The 
primary sequence of the TMD in ModBC is much shorter than that of SUR2B and little 
homology exits between them, thus modeling SUR2B should not be based on ModBC 
structure. On the other hand, the TMD topology of SAV1866 is same as those of SUR2B 
(Fig. 11-1), allowing modeling of SUR2B_core based on the SAV1866 template.  
 
 
 
92
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11-7. Introduction of a disulfide bond between ICL2 and NBD2 blocked PKA effects.  
A. Close view at residue Ala507 and Cys1408. The distance between Cαs of the two 
residues was ~8Å, allowing the two residues to form a disulfide bond. B. When Ala507 on 
SUR2B was mutated to cysteine, the channel activation by forskolin was blocked. C. Including 
3mM reduced glutathione in the pipette solution produced forskolin activation of the mutant 
channel. D. When the Cys1408 was mutated to serine, a similar residue that could not form 
disulfide bond, the Kir6.1/SUR2B_A507C_C1408S channel behaved like the wt channel. E. 
Summary of the forskolin effects on wt and mutants (***, P<0.001, compared to wt). 
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11.4.2. What is new in our SUR2B_core model? 
In our SUR2B_core model, NBD1 and NBD2 dimerize to form two nucleotide-
binding pockets at their edges, consistent with the models of previous studies on SUR1 
(Campbell et al., 2003; Campbell et al., 2004). A significant expansion of our model is to 
include TMDs and to show the interactions between TMDs and NBDs. SUR2B_TMD1 
interacts NBDs via two short segments ICL1 and ICL2. ICL1 interacts with both NBDs 
crossing the first nucleotide-binding region while ICL2 inserts deep into NBD2 (see Fig. 
11-1C). Therefore, TMD1 mainly interacts with NBD2. A similar cross-interaction is 
found in TMD2-NBD1. Our disulfide bond experiment and functional analysis indicate 
that Cys1408 in NBD2 does locate close to Ala507 in TMD1. Evidence supporting such a 
TMD-NBD cross-interaction also comes from a recent biochemical study (Zolnerciks et 
al., 2007) on human multidrug transporter (ABCB1), a close homologue of SURx.  
11.4.3. The importance of defining TMD-NBD interaction in SURx.  
The TMD-NBD interaction in SUR2B is not only important for PKA activation, 
but may also explain SUR-mediated channel gating by other ligands. For instance, it is 
well known that NBDs are important for Mg2+-nucleotide activation on KATP channels 
(Gribble et al., 1997; Shyng et al., 1997; Matsuo et al., 2002; Yamada & Kurachi, 2004). 
Although KCOs activate KATP channels via binding to segments in TMDs (Moreau et al., 
2005), NBDs are also necessary for KCO effects (Gribble et al., 1997; Shyng et al., 1997; 
Yamada et al., 2004), suggesting an allosteric modulation between these two distinct 
groups of channel activators. It is unclear how signals in NBDs are coupled to TMDs. 
Indeed, cis-interaction (TMD1 interacts with NBD1, TMD2 with NBD2) has been assumed 
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in SUR1 (Babenko & Bryan, 2003) and SUR2 (Yamada & Kurachi, 2004) based on the 
misassembled MSBA structure (Chang, 2003). Therefore, demonstration of the 
SAV1866-based NBD-TMD cross-interaction in SUR2B with experimental evidence 
contributes significantly to the understanding of the SUR-mediated gating of KATP 
channels. 
11.4.4. The mechanism of PKA activation.  
The SUR2B_core modeling enhances our understanding of the mechanism 
underlying PKA activation on vascular KATP channel. The Ser1387 is a critical 
phosphorylation site for PKA-dependent activation of Kir6.1/SUR2B in HEK cells (Shi 
et al., 2007b). Data from current study further support its role in the channel activation. 
Phosphorylation of the Ser1387 leads to a change in the NBD2 conformation and 
strengthens the interaction of the NBD2 with the ICL2 through the formation of a triad by 
residues in different protein domains. Every residue of the triad is critical, as shown in 
our mutagenesis analysis in the current and previous studies (Shi et al., 2007b). The 
interaction of p-Ser1387 and Arg1462 is apparently caused by the electronic attraction. 
The interactions of Tyr506 with the other two residues seem to rely on hydrogen bonds. 
Our simulation study indicates this triad is stable and might act as a primary force that 
changes the conformation of NBD2 and ICL2 at their interface. The ICL2 appears to move 
toward NBD2 while NBD2 is reshaped and moves toward ICL2, especially the α6-tail and 
the α3 helix and probably the β5 sheet as well. Thus the two domains interact with each 
other more tightly post phosphorylation. The NBDs thereby couple to the TMDs more 
effectively. Such a strong NBD-TMD coupling is likely to ensure the transfer of 
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mechanical forces and movements necessary for channel gating between these protein 
domains. Since such a coupling is weakened without Ser1387 phosphorylation, the 
mechanical forces and movements produced in NBDs may not be sufficient for channel 
gating. By enhancing the NBD-TMD interaction, therefore, vasodilators seem to be able 
to use the existing forces to augment the channel activity without producing additional 
mechanical work. It is noteworthy that the NBD-TMD force transfer depends on 
elaborate interactions of the triad, as restriction of these domains with disulfide bond does 
not lead to channel activation. 
 
 
 
Figure 11-8. Schematics of the PKA-dependent channel gating.  
A. Channel closure before Ser1387 phosphorylation. B. Binding ADP/ATP to NBDs 
changes the NBD conformation, which does not result in great channel activation without NBD-
TMD tight interaction. C. Ser1387 phosphorylation enhances the NBD-TMD interaction, allows 
coupling between the BND and TMD, and leads to channel activation. 
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11.4.5. Possible cooperation of PKA and nucleotide activators.  
The SAV1866 is crystallized in ADP (PDB: 2hyd) binding forms, which 
represents a dimer in NBDs. The NBD dimerization has been seen in almost all the ABC 
proteins and seen in simulation studies in NBDs of SUR1 (Campbell et al., 2003; 
Campbell et al., 2004). In the SUR2B_core model, the two NBDs form a hetero-dimer 
with two nucleotide-binding pockets at the interface. Such dimerization of NBD1 and 
NBD2 in SURx suggests a channel confirmation that is in an ‘active’ state. Nevertheless, 
the channel activity remains low (less than 10% of maximal activity by pinacidil 
according to our observation in previous and current studies), probably because the 
interaction between TMDs and NBDs is loose. PKA phosphorylation enhances the 
interaction of TMD1 (via ICL2) and NBD2 and thus drastically activates the channel to 
~40%. It is possible that PKA activation may rely on NBD dimerization caused by 
nucleotide binding. A study (Light et al., 2002) on the Kir6.2/SUR1 channel indeed 
indicates ADP concentration determines whether the channel is activated or inhibited by 
PKA. Though we have not observed inhibition on Kir6.1/SUR2B, we do see decreasing 
ADP concentration reduces PKA effects (unpublished data). It is of interest to know 
whether PKA can activate the channel in the absence of nucleotides.  
Demonstrating the molecular mechanism underlying PKA on channel activation 
is important in understanding the vasodilators effects on the KATP channel and vascular 
tone regulation. Additionally, discovery of the interaction between TMDs and NBDs 
contributes to a significant step in understanding SUR subunit mediated gating in KATP 
channels. 
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12. Result 3: A Unique Motif in Kir6.1 Consisting of 4 Phosphorylation 
Repeats Underlies the Vascular KATP Channel Inhibition by Protein 
Kinase C 
 
 
 
 
 
 
 
 
 
 
 
Manuscript submitted: Shi Y, Cui N, Shi W, Jiang C. (2007) A unique motif in Kir6.1 
consisting of 4 phosphorylation repeats underlies vascular KATP channel inhibition by 
protein kinase C. J Biol Chem, in press  
 
Note: The work was mostly done by Yun Shi (90%). Dr. Ningren Cui and Mr. Weiwei 
Shi did some patch clamp experiments. 
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12.1. Abstract 
Vascular ATP-sensitive K+ channels are inhibited by multiple vasoconstricting 
hormones via the PKC signaling pathway. However, the molecular substrates for PKC 
phosphorylation remain unknown. To identify the PKC sites, Kir6.1/SUR2B and 
Kir6.2/SUR2B were expressed in HEK293 cells. Following channel activation by 
pinacidil, the catalytic fragment of PKC inhibited Kir6.1/SUR2B but not Kir6.2/SUR2B 
currents. Phorbol 12-myristate 13-acetate (PMA, a PKC activator) had similar effects. 
Using Kir6.1-Kir6.2 chimeras two critical protein domains for PKC-dependent channel 
inhibition were identified. The proximal N-terminus of Kir6.1 was necessary for the 
channel inhibition. Since there was no PKC phosphorylation site in the N-terminus, our 
results suggest its potential involvement in channel gating. The distal C-terminus of 
Kir6.1 was also crucial, and it contains several consensus PKC sites. Mutation of Ser354, 
Ser379, Ser385, Ser391 or Ser397 to non-phosphorylatable alanine reduced PKC 
inhibition moderately but significantly. Combined mutations of these residues had greater 
effects. The channel inhibition was almost completely abolished when all five were 
jointly mutated. In-vitro phosphorylation assay showed that 4 of the serine residues were 
necessary for the PKC-dependent 32P incorporation into the distal C-terminal peptides. 
Thus, we identified a motif containing 4 phosphorylation repeats in the Kir6.1 subunit 
that is likely to underlie PKC-dependent inhibition of the Kir6.1/SUR2B channel. The 
presence of the phosphorylation motif in Kir6.1 but not in its close relative Kir6.2, 
suggests that the vascular KATP channel may have undergone evolutionary optimization 
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allowing it to be regulated by a variety of vasoconstricting hormones and 
neurotransmitters. 
12.2. Introduction 
In chapter 10 and 11, we demonstrated the activation of vascular KATP channels 
by vasodilators. In a separate study in our laboratory (Shi et al., 2007a), we have shown 
KATP channels are also inhibited by vasoconstrictors. The bidirectional modulation by 
vasoactive agents allows the channels to play a key role in controlling the VSMs 
membrane potential and regulating vascular tone. Experimental evidence suggests that 
vasoconstrictors act on the vascular KATP channel through the PKC signaling system; 
however, the mechanism is unknown.  
Our previous studies have shown that the Kir6.1/SUR2B channel and its 
counterpart in VMS cells are inhibited by vasopressin, and the channel inhibition can be 
abolished by specific PKC blockers (Shi et al., 2007a). Similar observations have been 
made by other groups with endothelin (Park et al., 2005), muscarinic M3 receptor agonist 
(Quinn et al., 2003) and angiotensin II (Hayabuchi et al., 2001b). The effect of 
angiotensin II on vascular KATP channel requires translocation of PKCε to plasma 
membranes (Hayabuchi et al., 2001b; Sampson et al., 2007). By comparing effects of 
acetylcholine M3-receptor on Kir6.1/SUR2B and Kir6.2/SUR2B channels, Quinn et al. 
(Quinn et al., 2003) suggest that the Kir6.1/SUR2B channel inhibition is mediated via a 
direct effect of PKC rather the change in PIP2 concentrations. They also show evidence 
for Kir6.1 phosphorylation using an in-vitro biochemical assay (Quinn et al., 2003). 
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Consistently, purified PKC inhibits the cloned Kir6.1/SUR2B and VMS-endogenous 
KATP channels in inside-out patches where cytosolic soluble components are absent (Cole 
et al., 2000; Thorneloe et al., 2002). Although these previous studies have significantly 
improved our understanding of the vascular KATP channel regulation by vasoconstrictors, 
the molecular substrate of PKC remain unknown. Therefore, we performed these studies 
to identify the critical protein domain and amino acid residues for PKC phosphorylation.  
12.3. Results 
12.3.1. PKC-dependent inhibition of the Kir6.1/SUR2B channel  
Kir6.1/SUR2B channels were expressed in HEK cells, and recordings were 
performed 2-5 days post-transfection. Kir6.1/SUR2B currents remained small during 8-
10 min of baseline recording, and were strongly activated by 10μmol/L pinacidil and 
inhibited by 10μmol/L glibenclamide (Fig. 12-1A, B). At maximum activation, 
application of 100nmol/L PMA strongly inhibited the Kir6.1/SUR2B currents 
(77.5±3.7%, n=19), which was blocked by PKCi, a specific PKC inhibitor (Fig. 12-1C, 
F). The inactive phorbol ester, 4α-phorbol-12,13-didecanoate (4α-PDD), did not affect 
Kir6.1/SUR2B currents (Fig. 12-1F).  
In inside-out patches, channel activity was low in the absence of nucleotides. The 
Kir6.1/SUR2B channel was activated in the presence of MgADP/ATP, which was further 
augmented with pinacidil application (Fig. 12-2A). When the catalytic fragment of PKC 
(cPKC) was applied to the internal patch membranes, the Kir6.1/SUR2B currents were 
markedly inhibited (61.1±3.8%, n=6, Fig. 12-2A, C). These results thus indicate that the 
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Kir6.1/SUR2B channel is inhibited by PKC independently of cytosolic soluble 
components, consistent with previous reports (Thorneloe et al., 2002). In contrast, PMA 
had no effects on Kir6.2/SUR2B channel in whole cell recordings (Fig. 12-1 D-F), 
neither the cPKC in inside-out patches (Fig. 12-2B, C), suggesting that the SUR2B 
subunit is not critical.  
 
Figure 12-1. Kir6.1/SUR2B and Kir6.2/SUR2B channels expressed in HEK293 cells. 
A. Whole-cell currents were recorded from a cell transfected with Kir6.1/SUR2B. 
Symmetric concentrations of K+ (145mmol/L) were applied to the pipette and bath solutions. The 
cell was held at 0mV, and pulse voltages from –120 to 80mV with a 20mV increment were 
applied. The current amplitude increased in response to pinacidil (Pin, 10µmol/L). The pinacidil-
induced currents were strongly inhibited by PMA (100nmol/L) and completely inhibited by 
glibenclamide (Glib, 10µmol/L). B. The time course for Kir6.1/SUR2B channel modulation. 
Whole-cell currents were recorded with a holding potential at 0mV and command pulses of –
80mV every 3 seconds. After the whole-cell configuration was formed, the cell was perfused with 
extracellular solution for a ~2 min baseline recording. The currents were strongly activated by 
pinacidil (10µmol/L), and the maximum activation was reached after 3-4 min of the exposure. 
The currents were maximally inhibited by PMA (100nmol/L) by 4-5min and could be further 
inhibited by glibenclamide. The lower panel shows individual currents produced by a single 
command pulse. C. Kir6.1/SUR2B currents were recorded with PKCi (10µmol/L) in the pipette 
solution. PKCi almost completely blocked Kir6.1/SUR2B current inhibition by PMA. D. E. 
Kir6.2/SUR2B currents were recorded from a transfected HEK293 cell with the same treatment 
as for the Kir6.1/SUR2B. PMA did not affect the pinacidil-activated Kir6.2/SUR2B currents. F. 
Summary of PMA effects on Kir6.1/SUR2B and Kir6.2/SUR2B currents activated by pinacidil. 
PMA inhibited Kir6.1/SUR2B currents strongly. The non-active PMA analog, 4α-phorbol 12, 13-
didecanoate (4α-PDD, 100nmol/L), had little effects on the Kir6.1/SUR2B currents. In the 
presence of PKCi, the PMA effect was reduced. PMA had no inhibitory effects on Kir6.2/SUR2B 
currents.  
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Figure 12-2. Effects of the recombinant catalytic fragment of PKC on Kir6.1/SUR2B and 
Kir6.2/SUR2B currents in inside-out patches.  
A. At baseline (BL) without nucleotides, the Kir6.1/SUR2B channels were closed. 
Application of 1mmol/L ATP / 0.5mmol/L ADP to the internal patch membrane slightly activated 
the currents, which were strongly activated by pinacidil (Pin, 10µmol/L). Application of cPKC 
inhibited the Kir6.1/SUR2B currents. B. Without nucleotides, the Kir6.2/SR2B channel was 
open. The channel was inhibited by 1mmol/L ATP / 0.5mmol/L ADP and activated by pinacidil. 
Unlike Kir6.1/SUR2B, cPKC has no effects on Kir6.2/SUR2B currents under the same 
experimental condition. C. Summary of cPKC effects on Kir6.1/SUR2B and Kir6.2/SUR2B 
currents that were activated by pinacidil. The Kir6.1/SUR2B currents were significantly inhibited 
by cPKC, while the Kir6.2/SURB currents were not affected.  
ATP/ADP Pin
cPKC Glib 
ATP/ADP Pin cPKC
%
 C
ur
re
nt
 in
hi
bi
tio
n
-10
0
10
20
30
40
50
60
70
A  Kir6.1/SUR2B 
B  Kir6.2/SUR2B 
C 
Kir6.1/SUR2B Kir6.2/SUR2B 
WS 
BL 
BL 
20pA 
2min 
60pA 
2min 
 
 
105
12.3.2. Critical protein domains for the PKC-dependent channel inhibition  
The differential PKC sensitivity of the Kir6.1/SUR2B from Kir6.2/SUR2B 
suggests that critical protein domains for PKC regulation are likely to be located on the 
Kir subunit. Thus, we constructed chimeric channels between Kir6.1 and Kir6.2 and 
expressed them with SUR2B in HEK293 cells. The Kir6.1 and Kir6.2 were divided into 
three regions: the N-terminus, the core sequence containing two transmembrane domains 
and the pore loop, and the C-terminus (Fig. 12-3). Six chimeras were obtained, all of 
which showed functional channels and were sensitive to pinacidil and glibenclamide. 
When the N-terminus of Kir6.1 was replaced with that of Kir6.2 (we named it 211), the 
channel inhibition by PMA was greatly diminished (Fig. 12-3A, D). A similar result was 
observed in the 112 chimera whose C-terminus derived from Kir6.2 (Fig. 12-3B, D), 
suggesting that both N- and C-termini are necessary for channel inhibition. Consistent 
with this, replacement of either the N-terminus or the C-terminus of Kir6.2 (122 and 221 
respectively) did not confer the PMA sensitivity to the chimeric channels (Fig. 12-3D). 
However, when both the N-terminus and the C-terminus of Kir6.2 were exchanged for 
their Kir6.1 counterparts, the 121 chimera responded to PMA just like Kir6.1 (Fig. 12-
3C, D). Therefore, both N-terminus and C-terminus appear critical for PKC-dependent 
channel inhibition.  
 
Figure 12-3. Responses of Kir6.1-Kir6.2 chimeras to PMA.  
All chimeric channels were expressed with SUR2B. A. When the N-terminus of Kir6.1 
was replaced with that of Kir6.2, PMA failed to inhibit the 211 channel. B. When the C-terminus 
of Kir6.1 was replaced with that of Kir6.2, the 112 channel lost its response to PMA. C. 
 
 
106
Construction of a chimera with both Kir6.1 N- and C-termini on the Kir6.2 core resulted in PMA 
sensitivity as wt Kir6.1/SUR2B. D. Summary of PMA inhibition of chimeras. Kir6.1 N-terminus, 
core and C-terminus refer to residues 1-71, residues 72-186, and residues 187-424, respectively. 
Kir6.2 N-terminus, core and C-terminus refer to residues 1-70, residues 71-176, and residues 177-
390.  
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We further divided the N-terminus into two segments and the C-terminus into 
three. All chimeras showed similar responses to pinacidil and glibenclamide as the wt 
channels. When the distal N-terminus was replaced the Kir6.1-21_111 channel responded 
to PMA to the same extend (71.1±4.2%, n=5, Fig. 12-4A) as Kir6.1. Replacement of the 
proximal N-terminus, however, partially but significantly eliminated PMA effects 
(36.7±7.8%, n= 5, Fig. 12-4B). A serine residue (Ser40) was found in the proximal N-
terminus of Kir6.1 but not in Kir6.2. When Ser40 was mutated to the corresponding site 
(Lys39) in Kir6.2, the channel Kir6.1-S40K was still inhibited as the wt Kir6.1, 
suggesting there is no PKC site in this segment. When the proximal C-terminus was 
replaced, the Kir6.1-11_211 responded to PMA as the same as the wt channel (Fig. 12-
4C). When either the middle or distal segment swapped, the Kir6.1-11_121 and Kir6.1-
11_112 channels’ responses to PMA were significantly diminished (Fig. 12-4D, E). PMA 
inhibition was further decreased in the chimera in which both the middle and the distal 
segments were derived from Kir6.2 (Kir6.1-11_122, Fig. 12-4F), although none of these 
chimeras showed complete block of PMA effects.  
 
Figure 12-4. Dissection of critical protein domains for the PKC-dependent channel 
inhibition.  
The N-terminus was further divided into two segments at residue 35 in Kir6.1 and residue 
34 in Kir6.2. The C-terminus was divided into 3 segments at residue 275 and 363 in Kir6.1 as 
well as residue 265 and 354 in Kir6.2. A. Kir6.1-21_111, the distal N-terminus of Kir6.1 replaced 
with that of Kir6.2, was inhibited by PMA as much as the wt Kir6.1/SUR2B channel. B. The 
PMA effect was disrupted in Kir6.1-12_111, where the proximal N-terminus of Kir6.1 was 
replaced. C. Replacement of the proximal C-terminus of Kir6.1 did not affect PMA sensitivity. 
 
 
108
D.-F. Replacement the middle segment of the C-terminus, the distal C-terminus or both disrupted 
channel inhibition to various degrees. G.-I. Construction of necessary protein segments in Kir6.2 
core. G. The distal C-terminus conferred partial PMA effects to the Kir6.2-core channel. H. 
When the middle and distal segments were switched, the channel displayed PMA inhibition with 
no significant difference from the wt Kir6.1 channel. I. In Kir6.2-21_221’ the distal C-segment 
was elongated from kir6.1 residues 364-terminus to 346-terminus, PMA fully inhibited the 
channel. J. Summary of the effect of N- and C-terminal segments on the channel inhibition. Data 
were obtained from 4-6 cells in each construct. The amino acid sequences of the distal C-termini 
(Kir6.1-346-424 and corresponding sequence in Kir6.2) are shown in the lower panel with 
putative PKC phosphorylation sites highlighted.  
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We then used chimeras with a Kir6.2 core and necessary N-terminal segment to 
search for the minimal requirement in the C-terminus for the PMA effect. Kir6.2-21_211 
showed full PMA sensitivity (69.9±6.7%, P>0.05 compared Kir6.1, n=4, Fig. 12-4H). 
Kir6.2-21_221 showed partial PMA sensitivity (33.7±3.1%, P<0.001 compared to Kir6.1 
and Kir6.2, n=5, Fig. 12-4G). By elongating the distal segment (Kir6.2-21_221’), the 
channel had full PMA response (78.8±2.5%, P>0.05 compared to Kir6.1, n=5, Fig. 12-
4I), suggesting that the distal segment appears to contain the essential C-terminus 
elements for PKC phosphorylation. 
12.3.3. Phosphorylation of a stretch of serine repeats in the C terminus by PKC  
There are multiple consensus PKC sequences in the distal C-terminus from 
residue 346 to the end residue, 424. Particularly remarkable are 4 SXRR/KXN repeats at 
residues 379, 385, 391 and 397. We thus performed alanine mutational screening for all 
consensus PKC sites. Mutation of any individual produced moderate but significant 
reduction of the PKC-dependent inhibition (Fig. 12-5B, E). Mutation of Ser354 in the 
same protein domain showed a similar effect. Combined mutations of 3 or 4 had greater 
effects (Kir6.1-3A, Kir6.1-4A, Fig. 12-5C, E). When all of these 5 serine residues are 
jointly mutated (Kir6.1-5A, Fig. 12-5D, E), the PKC-dependent channel inhibition was 
almost completely eliminated (Fig. 12-5A-E).  
 
Figure 12-5. Mutational analysis of potential PKC phosphorylation sites.  
A. Mutation Ser403 of Kir6.1 to alanine did not affect PMA inhibition. B. Mutation of 
Ser385 decreased PMA effects. C,D. When 4 and 5 potential PKC sites were mutated to alanine 
simultaneously, channel inhibition was largely eliminated. E. Summary of the mutations. 3A, 
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Kir6.1-S385A/Ser391A/S397A; 4A, Kir6.1-S379A/S385A/Ser391A/S397A; 5A, Kir6.1-
S354A/S379A/S385A/Ser391A/S397A. Data were obtained from 4-9 patches. White bars, 
P>0.05; Black bars, P<0.05. Application of chemicals was the same as in panel A.  
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To confirm that these serine residues are indeed phosphorylated, we generated a 
few C-terminal peptides of Kir6.1 (residues 346-424) with and without mutations on the 
serine residues. After extraction and purification, the peptides were subjected to SDS-
page separation, western blot, and in vitro phosphorylation. In Coomassie blue stain and 
Western blot, an ~52kd band was detected that was consistent with the peptide size (Fig. 
12-6B), while there was another ~49kd band indicating a degraded protein fragment. In 
vitro phosphorylation experiment showed strong 32P incorporation in both bands of the wt 
peptide (Fig. 12-6 C), consistent with functional assay. The strength of 32P incorporation 
was significantly reduced in the Kir6.1-3A peptide. The Kir6.1-4A and Kir6.1-5A 
peptides were weakly phosphorylated. Comparing the phosphorylation patterns, we found 
that Ser354 was not phosphorylated (See analysis in Fig. 12-6 legend). The Kir6.1-4A 
and Kir6.1-5A peptides remained to be phosphorylated to a very low degree, suggesting 
the presence of other unidentified PKC sites more distal to Ser397. Nevertheless, 32P 
incorporation to the Kir6.1-4A and Kir6.1-5A peptides was rather weak in comparison to 
the wt, suggesting that the Ser379, Ser385, Ser391, Ser397 are the major players in the 
PKC-dependent channel inhibition. 
 
Figure 12-6. In vitro phosphorylation on MBP-fusion peptides.  
A. Four MBP-fusion proteins were constructed by linking Kir6.1 distal C fragment 
(residues 346-424) to MBP with or without mutations on critical serine residues. The sequence 
underlined is the antigen for Western detection. B. All the constructs showed two bands with 
Western blot. The band around 52kd represented the intact fusion proteins (arrow), while the 
band of ~49kd was a degraded protein fragment (arrowhead). These bands were weakly detected 
in 3A, 4A and 5A by Western because mutations were made in antigen region. Lower panel 
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showed protein input colored with Coomassie blue. The heavy bands shown in Coomassie blue 
staining indicated the stronger degradation. C. In vitro phosphorylation showed strong 32P 
incorporation in both 52kd and 49kd bands in wt. The 32P incorporation was markedly reduced in 
3A. The 4A and 5A were only weekly phosphorylated in the 52kd band. By comparing 3A and 
4A, the phosphorylation of 49kd band on 3A must occur on Ser379. The 49kd of 4A was not 
phosphorylated also suggested that Ser354 was not phosphorylated. 
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12.4. Discussion 
The present study considers the molecular mechanism underlying the 
Kir6.1/SUR2B channel inhibition by PKC. The channel inhibition relies on a short motif 
consisting of 4 phosphorylation repeats in the Kir6.1 subunit. Graded channel inhibitions 
are produced by phosphorylation of different numbers of serine residues. The presence of 
the phosphorylation motif in the Kir6.1 but not in its close relative Kir6.2 suggests that 
the vascular KATP channel may have undergone evolutionary optimization allowing it to 
be regulated by a variety of vasoconstricting hormones and neurotransmitters.  
12.4.1. PKC inhibition is unique in Kir6.1/SUR2B channels 
PKC acts on several isoforms of KATP channels. Previous studies indicate that 
PKC activation leads to inhibition of the vascular Kir6.1/SUR2B channel, and this effect 
is likely to be mediated by direct phosphorylation of the channel protein (Cole et al., 
2000; Thorneloe et al., 2002). PKC activates the pancreatic isoform (Kir6.2/SUR1) and 
striated muscular isoform (Kir6.2/SUR2A) of KATP channels (Light et al., 2002). 
Expressed with SUR2B, the Kir6.2 channel is activated by PKC or shows no response, 
depending on recording conditions (Thorneloe et al., 2002; Quinn et al., 2003). A critical 
PKC phosphorylation site (Thr180) has been found in Kir6.2 mediating the fast channel 
activation (Light et al., 2002). It is unclear however whether a corresponding site in 
Kir6.1 (Thr190) plays a similar role, as mutation of the residue leads to a non-functional 
channel. PKC also causes the Kir6.2/SUR1 and Kir6.2/SUR2A channel internalization. 
Since the effect of PKC on the Kir6.1/SUR2B (inhibition) is clearly in contrast to Kir6.2-
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containing channels (activation or no effect), the Kir subunit is likely to be targeted by 
PKC regulation. The differential responses of the Kir6.1 and Kir6.2 to PKC allowed 
dissection of the critical protein domains using a chimeric strategy. Our studies on the 
Kir6.1-Kir6.2 chimeras have shown that the proximal N-terminus and distal C-terminus 
of Kir6.1 are critical for the PKC-dependent channel inhibition.  
12.4.2. The N-terminus might be involved in channel gating 
Interestingly only 7 residues are different between Kir6.1 and Kir6.2 proximal N-
termini, none of which can be phosphorylated. The lack of PKC phosphorylation sites in 
the protein domain suggests that it is likely to be involved in the channel gating or that it 
interacts with other domains to confer PKC sensitivity. Previous studies have shown that 
the proximal N-terminus is important for Kir6.2 channel gating by multiple channel 
regulators such as ATP and PIP2 (Cukras et al., 2002; Schulze et al., 2003a). A notable 
difference between Kir6.1 and Kir6.2 channels is that in the absence of nucleotide the 
Kir6.2 channels are spontaneously open while the Kir6.1 channels are completely closed 
(Kondo et al., 1998), a phenomenon that is also explained as fast inactivation of the 
Kir6.1 channels (Babenko & Bryan, 2001). Using Kir6.1-Kir6.2 chimeras, Kondo et al. 
found that both the N- and C-termini are important for this difference and that 5 residues 
in proximal N-terminus are largely responsible for the difference(Kondo et al., 1998). 
The Kir6.2 channels are also activated by intracellular H+ (Xu et al., 2001a). The pH-
dependent channel gating requires both N- and C-termini although there is only one 
protonation site (His175) located in the C-terminus (Piao et al., 2001; Xu et al., 2001b). 
The involvement of the proximal N-terminus in modulating channel activity has been 
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studied with different ligands, indicating that this region is indeed involved in Kir6.2 
channel gating rather than ligand binding (Wang et al., 2006; Wang et al., 2007). In 
addition to Kir6.2, the Kir2.3 channel is gated by acidic pH in an N-terminus dependent 
manner, where there is no protonation site (Qu et al., 2000). The requirement of N-
terminus for the PKC-dependent channel inhibition found in our current studies is thus 
consistent with these previous reports, suggesting that this protein domain is likely to be 
involved in interaction with other protein domain(s) in channel gating.  
12.4.3. The C-terminus contains a PKC motif with phosphorylation repeats 
The distal C-terminus (residues 346-424) of Kir6.1 is critical for PKC-dependent 
channel inhibition. This protein domain is a direct target of PKC as multiple PKC 
phosphorylation sites are found in this narrow region. Our functional analysis and in vitro 
phosphorylation assay indicate that there are at least four phosphorylation sites in this 
region, i.e., residues 379, 385, 391 and 397. Our patch clamp study suggests Ser354 is 
another, a result that is not supported by our in vitro phosphorylation assay. Therefore it 
is unclear whether Ser354 can be phosphorylated in vivo. Of them Ser397 in the human 
Kir6.1 has been previously reported to be phosphorylated by an unknown kinase in a 
global phosphorylation screening study (Olsen et al., 2006). None of the rest has been 
studied previously. Interestingly, the effects of these residue phosphorylations are 
additive or cumulative. Mutation of each individual reduces PKC effects by ~20%. 
Combined mutations of multiple residues have greater effects. Channel inhibition is 
almost completely abolished with mutations of all five serine residues. Multiple 
phosphorylation sites often results in sequential phosphorylation, which does not seem to 
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be the case in the Kir6.1/SUR2B, as our results suggest none of the residues shows a 
dominant effect over others. Of the 5 putative phosphorylation sites, 4 serine residues 
appear in a clear pattern of repeats (SXRR/KXN). To our knowledge, this is the first 
demonstration regarding such a phosphorylation motif in ion channels.  
12.4.4. A hypothetic model for gating mechanisms of PKC phosphorylation 
The distal C-termini of inward rectifier K+ channels play a critical role in channel 
trafficking and thus control the number of functional channels on the cell membrane (Ma 
et al., 2002; Yoo et al., 2004; Grishin et al., 2006; Pearson et al., 2006). There is an ER 
retention sequence (RKR, residues 381-383 in Kir6.1 and 369-371 in Kir6.2) (Zerangue 
et al., 1999), which warrants the Kir6 subunit targeting membrane together with the SUR 
subunit. A dileucine motif (Leu355, Leu356) in Kir6.2 is involved in channel endocytosis 
(Hu et al., 2003). Our results indicate that the distal C-terminus of Kir6.1 is also involved 
in controlling channel activity. In the narrow C-terminal region where last 4 PKC sites 
are found, there are 9 alkaline residues including the ‘RKR’ ER retention signal, making 
this region extremely positively charged. The positive charges appear to favor the open 
state in the presence of pinacidil or other channel openers. These charges are largely 
neutralized following phosphorylation of the serine repeats, which may attenuate the 
channel opening (Fig. 12-7). 
12.4.5. The formation of multiple PKC sites may undergo evolutionary selection.  
Why does the PKC phosphorylation motif exist in Kir6.1 but not in Kir6.2? The 
phosphorylation motif renders 16 phosphorylation sites in a KATP channel with four 
Kir6.1 subunits. This as well as the cumulative nature of each phosphorylation, may 
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allow the channel to be elaborately modulated according to the levels of PKC activation. 
This is consistent with the functional needs of the vascular KATP channel targeted by a 
variety of vasoconstricting hormones and neurotransmitters. The presence of the 
phosphorylation motif in the Kir6.1 but not in its close relative Kir6.2 suggests that the 
vascular KATP channel may have undergone evolutionary optimization serving for the 
vascular regulation under various physiological and pathophysiological conditions. 
 
 
 
 
 
 
 
 
 
 
Figure 12-7. A hypothetical model of PKC inhibition on Kir6.1/SUR2B channel.  
Two subunits of Kir6.1 are shown with SUR2B omitted. The Kir6.1 is shown in an open 
state representing that channel is pre-activated by pinacidil. The transmembrane segments are 
shown in yellow. The segments critical for PKC inhibition are shown in green including proximal 
N-terminus (tangle), the segment of residues 346-363 (circle) and the distal C-terminal segment 
(residues 363-424, hex-angle). The distal segment contains 9 positive charges; PKC 
phosphorylation (red) neutralizes the charges and leads to channel closure.  
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13. General Discussion 
13.1. Comparison of different working patterns in PKA and PKC phosphorylations 
The studies in this thesis have demonstrated the modulation of vascular KATP 
channels by two protein kinases that are activated by several vasoregulatory hormones. 
How do the phosphorylations of the same channel protein lead to completely different 
consequences in terms of channel activity? Comparison in the working patterns of PKA 
and PKC phosphorylation may provide some answers to the question.  
All PKC sites are located on the Kir6 subunits where ATP binds. It is possible 
that phosphorylation by PKC alters the channel sensitivity to ATP leading to channel 
inhibition. The ATP sensitivity of vascular KATP channels reported by different groups 
varies considerably (Quayle et al., 1997). Although the Kir6.1/SUR2B channel in hetero-
expression systems (Yamada et al., 1997) shows rather poor sensitivity to ATP as the 
KNDP channels found in smooth muscle cells isolated from rat portal veins (Zhang & 
Bolton, 1995; Zhang & Bolton, 1996), other reports show that vascular KATP channels are 
sensitive to ATP (Quayle et al., 1997). Considering that the recording conditions in 
different research groups may affect their results, a parallel study on Kir6.1/SUR2B and 
native KATP channels would provide more convincing information. Indeed, Cole et al. 
(Cole et al.) have compared ATP sensitivity of the vessel-native KATP channels with 
recombinant Kir6.1/SUR2B channels simultaneously, and found that the native channels 
are clearly inhibited by <1mM ATP while Kir6.1/SUR2B can only be inhibited by >5mM 
ATP. Thereby they concluded that the Kir6.1/SUR2B does not represent all properties of 
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native KATP channels. In our lab, we have observed ATP inhibition of both native 
channels and recombinant Kir6.1/SUR2B channels (Wang et al., 2003). The discrepancy 
in ATP sensitivity is not well understood. One possibility is that there are unknown 
factors missing in expression systems, which may have affected channel sensitivity to 
ATP. Another possibility is that the KATP channels with different phosphorylation states 
may have different ATP sensitivity through the change of electrostatic charges in local 
protein domains. The multiple phosphorylation sites identified in the current studies seem 
to support the second explanation as phosphorylations of some of serine residues may 
occur with the level of PKC activation that can vary with different physiological status, 
affecting the ATP sensitivity. Since different cells have different signal transduction 
cascades, the same receptor in different cell-types can produce different responses (Clark 
& Baro, 2007). Clearly, further studies are needed to fully understand the channel gating 
mechanisms resulting from the PKC phosphorylation. 
In contrast to PKC, the functional PKA site is located on SUR2B. There is only 
one in each subunit, although several other serine residues are also important for the 
PKA-dependent channel activation. How can the phosphorylation of a single residue in 
the SUR subunit remote from the ion-conductive pore have such a potent effect on the 
channel activity? As shown in our modeling study, the interdomain movement caused by 
phosphorylation is dramatic and widespread. The TMD1 moves toward NBD2 through 
ICL2, while the NBD2 also moves toward TMD1. In addition, significant conformational 
changes are seen in α6 helix and α3 helix. Even the β5 sheet (β sheets are most stable in 
the structure) moves toward TMD1 by ~3Å. Together the two domains show ~10Å 
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movement following Ser1387 phosphorylation by PKA. Such a large scale of movements 
can certainly produce the necessary mechanical forces for channel gating, providing 
plausible explanations why phosphorylation of a single site in auxiliary β subunit is 
adequate for activation of the Kir6.1/SURB channel that is normally inhibited by 
phosphorylation of multiple residues in the pore-lining Kir6.1 subunit by PKC. In 
addition, it is possible that the PKA phosphorylation has cooperative effects on ADP 
binding through an allosteric mechanism, leading to enhanced channel activity by several 
fold (>500%, see discussion in chapter 12.4.5). 
13.2. Unique bi-directional regulation of the vascular KATP channels  
Although all KATP channels are similar in their basic structure, channel 
modulation by intracellular nucleotides, extracellular messengers and intracellular signal 
pathways are quite different. Channel regulation by hormones and transmitters is 
particularly important for vascular KATP channels, while the pancreatic and cardiac KATP 
channels are prominently regulated by metabolites. There are reports of Kir6.2/SUR1 
(pancreatic) and Kir6.2/SUR2A (cardiac) channel regulation by hormones and associated 
intracellular signaling pathways; however, the data are contradictory and the pictures of 
the effects are elusive (Table 13-1,2).  
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Table 13-1. Summary of PKA effects on recombinant KATP channels.  
KATP channel Effects Phosphorylation sites References 
Kir6.2/SUR1 
 
 
Activation Kir6.2_Thr224 Lin, 2000 
Activation Kir6.2_Ser372 Beguin, 1999 
Inhibition  SUR1_Ser1448 Light, 2002 
Kir6.2/SUR2A Activation Kir6.2_Thr224 Lin, 2000
Kir6.2ΔC36 Activation Kir6.2_Thr224 Lin, 2000 
Kir6.1/SUR2B 
 
Activation 
Kir6.1_Ser385  
SUR2B_Thr633 & Ser1465 Quinn, 2004 
Activation SUR2B_Ser1387 Shi, 2007b 
 
The effects of Kir6.1/SUR1 channel regulation presented in literature. Both activation 
and inhibition have been reported. The PKA phosphorylation sites on Kir6.2/SUR1 channel are 
debatable. PKA only activates Kir6.1/SUR2B channel, consistent with native vascular KATP 
channel. Concerning Kir6.1/SUR2B channels, a previous report is inconsistent with our results. 
Possible reasons are discussed in the text in Chapter 10.  
 
Table 13-2. Summary of PKC effects on recombinant KATP channels.  
KATP channel Effects Phosphorylation sites References 
Kir6.2/SUR1 Activation T180 Light, 2000 
Kir6.2/SUR2A Activation  T180 Light, 2000 
Kir6.2ΔC26 Activation T180 Light, 2000 
Kir6.1/SUR2B 
 
Inhibition NA 
Quinn, 2003;  
Thorneloe, 2002 
Inhibition 
Kir6.1_Ser379, Ser385, 
Ser391 & Ser397 Shi, et al. 2008 
Kir6.2/SUR2B 
 
Activation NA Thorneloe 2002
No effects in the 
presence of pinacidil  
Quinn 2003;  
Data in this thesis. 
 
PKC activates Kir6.2 channels but not in the presence of pinacidil. We observed that 
Kir6.1/SUR2B channel is inhibited by PKC, consistent with previous observations. We also 
demonstrate PKC phosphorylation sites in Kir6.1 subunit.  
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The reported PKA effects on Kir6.1/SUR1 channels found in the pancreas and in 
brain are contradictory. PKA appears to activate the channels via phosphorylation at 
Kir6.2_Thr224 (Lin et al., 2000) or Ser372 (Beguin et al., 1999). A human specific site 
on SUR1 is also proposed to have baseline phosphorylation (Beguin et al., 1999). 
Another study however shows the KATP channels in the pancreas are likely inhibited by 
glucagon-like peptide that activates the cAMP-PKA pathway (Light et al., 2002). A 
phosphorylation site (Ser1448) in SUR1 seems to mediate the inhibitory effects. The 
inhibition of PKA can turn to activation with different ADP concentrations (Light et al., 
2002). While, the discrepancy of the PKA effects on Ki6.2/SUR1 channel is not fully 
understood, there seems to be PKA-independent channel inhibition mediated by a cAMP-
EPAC pathway (Kang et al., 2006), making the situation more complicated. The 
activation of the cAMP-PKA pathway causes insulin release from the β-cells probably 
via KATP-independent pathways (Miura & Matsui, 2003).  
Activation of the Gq pathway by membrane receptors causes PIP2 degradation 
and PKC activation. All Kir6.2 channels are activated by PKC (Light et al., 1995; Light 
et al., 2000). When the channels are pre-activated by pinacidil, PKC does not have 
further effects probably because the channels have reached saturating activity (Quinn et 
al., 2003), consistent with the observation in this thesis. On the other hand, activation of 
α-adrenergic receptors causes inhibition on cardiac KATP channel (Kir6.2/SUR2A) via 
break-down of PIP2 (Xie et al., 1999; Haruna et al., 2002). Quinn has also proposed that 
activation of M-receptors leads to inhibition of Kir6.2/SUR2B channel via decrease of 
PIP2 concentration (Quinn et al., 2003). Therefore, it is debatable whether Kir6.2 
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channels are activated or inhibited following activation of Gq signaling system by 
membrane receptors.  
In contrast, vascular KATP channel regulation by hormones and intracellular 
signaling systems is consistent in the literature. Activation of the Gs pathway clearly 
leads to channel activation mediated through PKA phosphorylation as shown in the 
current studies. Activation of the Gq pathway only results in channel inhibition via PKC 
phosphorylation, while PIP2 concentration change in the physiological range has little 
effects on the channel activity (Quinn et al., 2003). The bi-directional effects by protein 
kinases seem to fulfill the functional needs of the channels in regulating vascular tone 
regulation under multiple physiological conditions where the vessels are exposed to 
vasodilating and vasoconstricting hormones.  
13.3. Functional impacts of the PKA and PKC phosphorylation.  
Although only β-adrenergic receptors have been studied in this thesis, the 
molecular mechanisms revealed in these studies for PKA activation and PKC inhibition 
can be applied to explain the action of the vasoactive agents in multiple physiological and 
pathophysiological situations. I generally refer those factors as to hormones in this thesis. 
However, the vasoactive agents are clearly from all kinds of resources that we can think 
of, including circulating hormones, neurotransmitters, secretes from vascular endothelial 
cells or metabolites released by local tissues.  
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13.3.1. Circulating hormones  
 Norepinephrine and epinephrine have bi-directional effects on vascular tone. 
They activate KATP channels through the PKA pathway in the coronary, cerebral and 
skeletal muscular arteries where β-adrenergic receptors are dominate. The channels are 
inhibited via the PKC pathway in arteries of skin and gastrointestinal tract through the α-
adrenergic receptors (Bonev & Nelson, 1996). Therefore, the PKA and PKC 
phosphorylations of vascular KATP channels are the likely molecular basis for the vascular 
effects of epinephrine and norepinephrine. Another two vasoactive hormones, 
angiotensin II and vasopressin, can constrict arterials partially via inhibition of vascular 
KATP channels in a PKC-dependent manner (Miyoshi & Nakaya, 1991; Kubo et al., 1997; 
Hayabuchi et al., 2001b; Shi et al., 2007a). In addition, angiotensin II may reduce KATP 
channel activity by inhibition of PKA (Hayabuchi et al., 2001b).  
13.3.2. Other factors released from nerve terminals  
Calcitonin gene-related peptide (CGRP) and vasoactive intestine polypeptide 
(VIP) are strong vasodilators found in the sensory nerve terminals in vascular smooth 
muscles of cerebral arteries (Edvinsson, 2001). They are released when the tissues are 
subject to noxious stimuli (Quayle et al., 1997). Over-release of the neuropeptides causes 
over-dilation of cerebral arteries which may be related to headache and migraine 
(Edvinsson, 2001). The CGRP (Nelson et al., 1990a; Quayle et al., 1994; Wellman et al., 
1998) and VIP (Yang et al., 2007) have been shown to activate vascular KATP channels 
via the PKA pathway. Since the PKA phosphorylation of Kir6.1/SUR2B is critically 
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involved in the pathology, it is possible to develop new therapies by interference with the 
PKA pathway or phosphorylation process.  
13.3.3. Endothelium-derived vasoregulators 
Vascular endothelial cells can release endothelium-dependent relaxation and 
contraction factors regulating blood flow in local tissues. NO released from the 
endothelium cells causes vasodilation, where KATP channels may be involved. The 
intracellular pathway for NO-induced KATP activation is unclear but possibly via PKA 
signaling pathway (Murphy & Brayden, 1995; Brayden, 2002). The endothelium-derived 
hyperpolarization factors are recently found to be epoxyeicosatrienoic acids (Michaelis & 
Fleming, 2006). The epoxyeicosatrienoic acids have been shown to activate vascular 
KATP channels in mesenteric artery via the PKA pathway (Ye et al., 2005; Ye et al., 
2006). Endothelium also releases vasoconstrictors such as endothelin (Marasciulo et al., 
2006). Its vasoconstrictive effect is partially caused by inhibition on KATP channels via 
PKC (Miyoshi et al., 1992; Park et al., 2005). Therefore, PKA and PKC 
phosphorylations of Kir6.1/SUR2B channels are some of the important molecular 
mechanisms mediating endothelium-mediated regulation of regional blood flows. 
13.3.4. Local mediators released from damaged tissues  
The PKA action on vascular KATP channels can also explain the channel 
protective effects on local tissues when they are subjected to metabolic stress such as 
hypoxia and ischemia. Hypoxia and ischemia are not only metabolic challenges but also 
lead to release of variable vasodilatory signal molecules including NO, K+, H+ and 
adenosine by damaged local tissues (Obata, 2002). The vasodilatory effect through 
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adenosine is remarkable as blockade of adenosine receptors reduces about 50% of 
ischemia reperfusion-induced vessel dilation in cerebral arteries (Rudolphi et al., 1992; 
Nakhostine & Lamontagne, 1993). The adenosine effects are partially mediated via 
activation of the KATP channels, as glibenclamide diminishes significantly the adenosine-
induced vasodilation, and adenosine is known to activate the PKA system (Kleppisch & 
Nelson, 1995). Thus, PKA phosphorylation of the Kir6.1/SUR2B channel appears to 
underlie the adenosine-induced vasodilation.  
13.3.5. Channel regulation by anesthetics.  
In addition to endogenous vasoregulators, several clinically used anesthetics also 
act on the KATP channels. For example, isoflurane seems to activate vascular KATP 
channels via PKA (Tanaka et al., 2007). This effect depends on SUR2B subunit (Fujita et 
al., 2006), consistent with our current findings that PKA sites are located on SUR2B.  
13.4. The vascular KATP channel as a key integration molecule in vascular tone 
regulation  
Intracellular ATP, ADP, pH and phospholipids modulate activity of KATP 
channels. Such modulations allow KATP channels to function as a linker between the 
change of the intracellular metabolic states and membrane potentials (Aguilar-Bryan & 
Bryan, 1999). Intracellular and extracellular pH levels decrease in local tissues seen in 
heavy exercise, fasting, diabetes and in various types of metabolic stress including 
hypercapnia, hypoxia and ischemia. Previous studies in our laboratory have shown that 
pancreatic and cardiac KATP channels are strongly activated by hypercapnia and 
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intracellular acidosis (Xu et al., 2001a; Wu et al., 2002b; Li et al., 2005). Thus, pH is 
another potent regulator of KATP channels in addition to ATP, ADP and phospholipids. 
The modulations of KATP channel activity by protons, ATP and ADP are via direct 
binding on Kir6.x or SURx as shown in numerous previous studies (Matsuo et al., 2000; 
Xu et al., 2001a; Dabrowski et al., 2004). The modulation of the metabolites leads to the 
change in channel activity, allowing KATP channels to sense and integrate metabolic 
signals under different physiological conditions. The capacity of vascular KATP channels 
to detect the intracellular ATP/ADP ratio (Ashcroft & Gribble, 1998) and pH changes 
(Wang et al., 2003) allow autoregulation of regional blood flows according to activity 
and energy consumption in local tissues.  
Experimental data in this thesis suggest that channel regulation by protein kinases 
is another important regulatory mechanism. Such a regulatory mechanism enables 
vascular KATP channels to control vessel diameters by multiple extracellular vasoactive 
molecules (Fig. 13-1). Some of the vasoactive substances are released during hypoxic 
ischemia, leading to stronger vasodilation and a greater increase in local blood flow than 
metabolic regulation alone.  
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Figure 13-1. Regulation of vascular KATP channels by metabolites and vasoactive hormones. 
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Channel regulation by vasoconstricting hormones is also strong and may be 
predominant over metabolic regulation in some situations. Hypertensive circulating 
hormones such as adrenaline, vasopressin and angiotensin II dictate blood supply to local 
tissues according to systemic needs by shutting off KATP channel activity through 
activation of PKC, even though the cellular metabolic activity may demand more blood 
in local tissues. Taken together, the vascular KATP channels integrate signals of the 
complex vasoregulation network into seemingly well-organized regulation of VSM 
contractility. Channel modulation by different kinases can maintain the systemic blood 
pressure. On the other hand, blood supply can be dynamically regulated according to the 
functional needs of the tissues via metabolites, local vasoactive mediators, circulating 
hormones and neurotransmitters under various physiological conditions.  
The capability of KATP channels to regulate blood flow may play a role in 
pathological conditions. For example, although appropriate release of CGRP causes 
dilation of cerebral arteries that would increase blood flow according to nerve activity, 
strong activation of KATP channels by CGRP leads to over-dilation of the cerebral arteries 
causing primary headache (Edvinsson, 2001). A widespread over-activation of KATP 
channels in a large number of arteries may produce systemic hypotension seen in sepsis 
(Landry & Oliver, 1992).  
The capability of KATP channels in vascular tone regulation suggests potential 
therapeutics for the control of abnormal vascular contractility. Channel openers have 
been used in treatment of hypertension and vasospasm (Edwards & Weston, 1993). The 
channel inhibitor glibenclamide may help to maintain blood pressures in sepsis (Landry 
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& Oliver, 1992). All of these rely on the understanding how the KATP channels regulate 
vascular tone and of the molecular mechanisms that regulate KATP channel activity. In 
this regard, this thesis provides information about the channel regulation at molecular 
level, which may eventually help develop therapeutic strategies.  
In conclusion, vascular KATP channels are activated and inhibited by PKA and 
PKC signaling systems, respectively. These effects rely on intrinsic properties of the 
channel protein that are present in Kir6.1 and SUR2B but not in their close relatives. By 
targeting on these intrinsic molecular and biophysical properties, vasodilators and 
vasoconstrictors can modulate the channel activity as well as vascular tones. The 
understanding of these intrinsic molecular and biophysical properties therefore provides 
information of cardiovascular physiology and helps the design of effective therapeutical 
approaches for cardiovascular diseases. 
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